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 ABSTRACT 
The general aim of this thesis was to explore the associations between sex hormones 
and high blood pressure in men and women and to investigate their further role in the 
development of acute myocardial infarction particularly with regard to the large 
effect of type 2 diabetes, especially seen in women. Differences in levels of sex 
hormones and their specific effects in men and women might partially explain the 
differences in cardiovascular risk between men and women. Our specific aims were 
to investigate the relationship between sex hormones and high blood pressure as a 
major risk factor for cardiovascular disease, to investigate mechanisms that control 
the concentrations of sex hormone-binding globulin (SHBG), to investigate 
testosterone as a risk factor for AMI in men and women, to explore the modifying 
effect of type 2 diabetes on the outcome, and to investigate the association between 
sex hormones and cardiovascular disease, stroke and AMI, in men and women with 
or without type 2 diabetes. 
This thesis included studies on 2 cohorts:1. A population survey in the municipalities 
of Vara and Skövde (VSC) 2002-2005 (n=2816, aged 30-74 years, 50% female, 
participation rate 76%); 2. A population survey in the municipality of Skara (SC3) 
1993-1994 (n=1109, aged 40-80+ years, 50% female, participation rate 79%). 
Findings: Low concentrations of SHBG were associated with high blood pressure in 
men, whereas SHBG was independently associated with hypertension in 
postmenopausal women. We also found that insulin levels were independently 
associated with SHBG levels. Low testosterone levels in men with diabetes 
significantly predicted AMI independently of major cardiovascular risk factors. 
Endogenous estradiol concentrations were significantly associated with stroke risk in 
both sexes but with opposite relationships; estradiol was associated with reduced 
stroke risk in women, but with increased stroke risk in men. 
In conclusion, concentrations of sex hormones predicted cardiovascular morbidity in 
both men and women, albeit differently. While testosterone was protective in men, 
estradiol and SHBG were protective in women. Moreover, SHBG seems to play an 
active role in the modulation of sex hormone effects, as it was found to be 
independently associated with hypertension. However, more studies are needed to 
explore the association of this globulin with diabetes and hypertension, in order to 
confirm our results suggesting a role of insulin in the control of SHBG. 
Correspondingly, the effects of estradiol in men seem negative while the effects of 
testosterone in women were uncertain. Thus, in each sex the characteristic hormone 
supports health. Diabetes also modified the association between concentrations of 
sex hormones and CVD in both sexes. These modifications might at least partially 
explain the loss of cardiovascular protection in women when they develop type 2 
diabetes. 
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ABSTRAKT  
Det övergripande syftet med denna avhandling var att undersöka sambandet 
mellan könshormoner och högt blodtryck hos män och kvinnor samt att 
utforska deras roll i utvecklingen av akut hjärtinfarkt. Skillnader i nivåer av 
könshormoner och deras specifika effekter hos män och kvinnor skulle, 
åtminstone delvis, kunna förklara skillnaderna i kardiovaskulär risk mellan 
män och kvinnor. Våra specifika syften var att undersöka associationen 
mellan koncentrationer av könshormoner och högt blodtryck, att undersöka 
mekanismer som styr halterna av könshormonbindande globulin (SHBG), att 
undersöka testosteron som en riskfaktor för akut hjärtinfarkt respektive hjärt- 
och kärlsjukdom hos män och kvinnor, samt att utforska den modifierande 
effekten av typ 2 diabetes på dessa resultat.  
Avhandlingen baseras på 2 kohorter: 1. En befolkningsundersökning i 
kommunerna Vara och Skövde 2002-2005 (n= 2816, i åldern 30-74 år, 
deltagandet 76 %), 2. En befolkningsundersökning i kommunen Skara 1993-
1994 (n = 1109, i åldern 40 till 80+ år, deltagandet 79 %).  
Låga halter av SHBG var förknippade med högt blodtryck hos män, medan 
detta samband hos kvinnor var begränsat till de som var äldre än 50 år. Vi 
fann också att insulinnivån hade ett oberoende samband med SHBG för båda 
könen. Låga testosteronnivåer hos män med diabetes förutspådde akut 
hjärtinfarkt oberoende av vanliga kardiovaskulära riskfaktorer. Vi fann också 
att endogena koncentrationer av estradiol hade en signifikant betydelse för 
stroke hos båda könen: skyddande hos kvinnor men en riskfaktor för män. 
Sammanfattningsvis förutspådde halter av könshormoner kardiovaskulär 
morbiditet hos både män och kvinnor, om än på olika sätt. Medan testosteron 
var skyddande hos män, var estradiol och SHBG skyddande i kvinnor. 
Dessutom verkar SHBG spela en aktiv roll i moduleringen av 
könshormonernas effekter. Studier som undersöker mekanismer bakom 
associationen mellan SHBG och diabetes/hypertoni behövs. Våra resultat 
tyder även att endogent insulin spelar roll för kontrollen av SHBG.  
Slutligen, estradiol hade negativa effekter hos män medan effekterna av 
testosteron hos kvinnor var osäkra. Således var det karakteristiska hormonet 
för respektive kön kopplat till en bättre hälsa. Diabetes modifierade också 
sambandet mellan halter av könshormoner och hjärtkärlsjukdom hos båda 
könen. Dessa effekter kan åtminstone delvis förklara varför kvinnor förlorar 
sitt naturliga skydd mot hjärtsjukdom när de insjuknar i typ 2 -diabetes. 
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1 INTRODUCTION 
Cardiovascular disease (CVD) is the major cause of death in developed 
countries[1]. Cardiovascular mortality and morbidity differs greatly between 
men and women. Women seem to be protected and are affected by these 
diseases more rarely and later in life compared to men [2]. Hormonal 
differences between men and women may, speculatively, play a role in these 
discrepancies regarding cardiovascular morbidity and mortality. In light of 
such hormonal differences, we would expect testosterone to have an adverse 
effect or estrogen to have a protective effect or both. Surprisingly, the 
majority of studies suggest a protective effect of testosterone in men [3-5] 
while the effects of estrogen in women are not so clear [6-8]. Moreover, the 
sex-specific cardiovascular protection in women seems to disappear when 
they develop type 2 diabetes. In fact, women with type 2 diabetes have age-
specific cardiovascular risk that is very similar to the risk in men. Thus, two 
key questions are: 1) How much of the differences in risk can be explained 
by the effects of sex hormones? 2) Is there any other factor that modulates 
the effects of sex hormones or that may obscure these effects? 
1.1 Sex hormones, production and physiology 
1.1.1 Men 
The production of sex hormones starts with as illustrated in Figure 1. In 
men, sex hormones are produced in the testis, and the main hormone is 
testosterone. Testosterone is then converted to the more potent hormone 
dihydro-testosterone. Aromatase converts part of testosterone to estradiol in 
testis, brain, bones, adipose tissue, and the activity increases with age, 
Figure 1. Production of sex hormones 
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obesity and hyperinsulinemia [9]. Testosterone and estradiol are liposoluble 
hormones and circulate bound to albumin or sex hormone-binding globulin 
(SHBG) (Figure 2).  
The free fraction of testosterone together with the fraction bound to serum 
albumin constitutes the bioavailable fraction. However, it is unknown 
whether the fraction bound to SHBG is bioactive or whether it is only a 
reservoir of sex hormones in the circulating blood stream. 
Dehydroepiandrosterone (DHEA) is a pre-hormone produced in the adrenals 
and converted into sex hormones in the target tissues by local enzymes. 
DHEA is responsible for about 50% of active sex hormones in men aged 60 
years or older [10]. DHEA and sulphated-DHEA serve as reservoirs of sex 
hormone in the circulation as their concentrations are high, and both forms 
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receptors is responsible for the mineralization and the closure of the 
epiphysis. In the brain, estradiol is responsible for sexual behaviour. 
SHBG is the major carrier of sex-hormones in the blood stream. SHBG is 
mainly produced in liver. In men the levels of SHBG increase with aging 
[12] and in women they decrease during the menopause and then remain 
constant [13, 14]. Hypothyroidism and the metabolic syndrome are 
associated with low concentrations of SHBG and hyperthyroidism, and 
anorexia is related to higher concentrations of SHBG [15-18]. Estradiol also 
seems to induce production of SHBG in the liver, whereas no such effect is 
seen from testosterone. Although glucose seems to inhibit the production of 
SHBG, the effects of insulin are debated [19]. Although SHBG has been 
considered as a transport protein, there is growing evidence showing a more 
active role for this protein in the modulation of the effects of sex hormones. 
In fact, receptors for SHBG in the membrane of prostatic tissue have been 
shown [20], and these receptors seem to activate an increase of c-AMP 
concentrations if the receptor is activated by the complex SHBG-Hormone 
[21, 22] (Figure 3).  
The combined effect of the testosterone decrease and the SHBG increase in 
aging men results in a dramatic attenuation of the physiological effects of 
Figure 3. Model of receptor-SHBG-steroid system. 
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testosterone. This decrease is, however, gradual and slow in contrast to the 
situation in women where there is a relatively steep decline in estrogen 
production coinciding with the onset of menopause. 
1.1.2 Women
Similar to testosterone in men, the production of estradiol in women starts 
from cholesterol (Figure1). In fertile women, the major part of estradiol is 
produced in granulosa cells of ovaries and involves the conversion of 
androstenodione into estrone, and the further conversion of the latter into 
estradiol. Another form of estradiol production is through the aromatization 
of testosterone in adipose tissue. Adrenal glandules also produce estradiol in 
minor quantities. The concentrations of estradiol vary during the ovarian 
cycle and are involved in ovulation (Figure 4).  In postmenopausal women, 
there is a cessation of estradiol production in the ovaries, and the major part 
of estradiol is then produced by aromatization of circulating androgens. The 
levels of estrogen in postmenopausal women are comparable to the levels of 
estrogen in men. However, there are large sex-differences in the levels of 
testosterone during the entire lifespan, with 10 times higher testosterone 
levels in men compared to women. Even if the levels of testosterone tend to 
decrease in women after menopause, the decrease is attenuated as the 
production of androgens in stromal tissue of ovaries continues after the 
menopause [23], and the production of androgens in the adrenals seems not 
to be influenced by the menopause. DHEA and sulphated-DHEA decrease 
Figure 4. Estrogen production in women during lifespan.  
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gradually in women and this decrease is reflected in testosterone levels. The 
levels of DHEAS during the menopause are only 50% of those at ages 25-30. 
Similar to men, only 2% of estradiol circulates free and is responsible for the 
hormonal effects [24]. In aging women, the levels of SHBG do not increase 
as they do in men. The levels of SHBG in women are higher than in men 
after puberty, probably because of the inductive effect of estradiol in the 
liver. These levels decrease in the menopause and are then almost constant in 
older women. 
1.2 Sex hormones and cardiovascular risk 
1.2.1 Men 
Testosterone 
Androgens have previously been considered to decrease glucose tolerance, 
induce hyperinsulinemia, and increase cardiovascular risk in women as well 
as in men. In contrast to these notions, observational studies in men have 
shown an association between insulin resistance, diabetes and low s-
testosterone [25, 26]. The association with metabolic syndrome and diabetes 
seems to be bidirectional. On the one hand, the expansion of the adipose 
tissue in obesity increases the activity of aromatase in the adipose tissue, 
resulting in a decrease of testosterone levels [17, 18]. On the other hand, low 
testosterone concentrations diminish insulin sensitivity and cause obesity in 
castrated men [27]. Low s-testosterone has also been associated with lower 
HDL levels in men [28], and there are studies that show beneficial effects of 
testosterone on arterial stiffness [29]. In several studies, low levels of 
endogenous testosterone have been associated with hypertension [30], and 
this relationship seems to be independent of other factors related to  the 
metabolic syndrome [31]. Although these observations suggest a more direct 
effect of testosterone on the vessels, the mechanisms are still unknown. It 
has been speculated that testosterone receptors in the vessels have a 
vasodilator effect in coronary vessels [32]. To our knowledge, this 
observation has not been confirmed in other studies and is based on findings 
in arteries with advanced atherosclerosis. Thus, the effect in normal vessels 
is still unknown. The modulating effect of testosterone [33] in inflammation 
might explain the effects of testosterone in vessels. Inflammation per se is 
related to an increase in peripheral resistance and hypertension [34]. Several 
prospective observational studies in elderly men have shown a strong 
association between low levels of testosterone and cardiovascular mortality 
[35]. Moreover, castrated men have significantly higher rates of CVD [36-
38]. However, observations of the effects of testosterone in middle-aged men 
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with regard to cardiovascular mortality and morbidity are lacking. The 
absence of evidence might be attributable to lack of statistical power due to 
the rarity of these events in a younger population. Another biological reason 
of for findings only in older populations might be differences in the effect of 
testosterone in older and younger men, respectively. Aging in the endothelial 
tissue might be a cause of vulnerability to cardiovascular disease, in that the 
role of testosterone may become more important for the endothelial function 
in older than in younger individuals with intact endothelium. Type 2 diabetes 
is associated with early vascular aging [39, 40]. Therefore, analyses 
comparing the effects of testosterone in men with and without diabetes, 
respectively, would represent a good way of modelling the differing effects 
of testosterone on cardiovascular endpoints in younger and older men. 
Testosterone replacement therapy in men is used if symptoms of 
hypogonadism are associated with lower levels of testosterone [41, 42]. 
Although a good effect is observed in the metabolic syndrome [43], 
randomized controlled trials with hard endpoints in individuals with high 
risk are still lacking. 
Estradiol 
Testosterone is the most important source of estradiol in men [11]. Although 
the activity of aromatase increases with age, the concentration of estradiol 
remains almost unchanged as testosterone levels decrease. Estradiol is 
important in men in the process of the closure of the epiphysis, the control of 
the function of pituitary production of luteinizing hormone and in sexual 
behaviour. The effect of estradiol with regard to cardiovascular risk in men is 
uncertain. Epidemiological prospective studies investigating the effects of 
estradiol concentrations in the intima media have yielded contrary results 
[44-46]. Also, one prospective study has shown that high levels of 
endogenous estradiol levels predict stroke [47]. In the mid-1960s the 
Coronary Drug Project tested two doses of exogenous estrogen for the 
prevention of heart disease in men. Both estrogen arms were terminated 
early due to an excess of adverse events [48]. Similarly, men receiving 
estrogen for prostate cancer have been shown to have an increased risk of 
CVD [49]. Although epidemiological studies show in general an adverse 
effect of exogenous estradiol and an uncertain effect of endogenous 
estradiol, the mechanisms underlying these associations remain unexplained. 
Sex hormone binding globulin (SHBG) 
Epidemiological studies have shown an association between low levels of 
SHBG and the metabolic syndrome and diabetes mellitus, respectively[17, 
18, 25, 50]. In fact, high levels of glucose in subjects with metabolic 
syndrome inhibit the production of SHBG[19]. In 2009, Ding et al. could 
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show that in both men and women low concentration of SHBG predicted 
type 2 diabetes mellitus [51]. The paper also reported that genetic variants 
associated with lower levels of SHBG production could also predict diabetes. 
The same observation was made in another cohort of only men, where 
SHBG, but not testosterone, predicted type 2 diabetes [52]. These results 
combined with the presence of membranous receptors for SHBG indicate 
that this globulin plays a more active role in the modulation of sex-hormone 
effects and in glucose metabolism in general. Moreover, a recent study in 
post-menopausal women has shown an association between SHBG and the 
incidence of hypertension [50]. Taken together, these findings suggest an 
important role for SHBG as a predictor of cardiovascular disease. Only a few 
studies have investigated the predictive value of SHBG for CVD-risk, and 
the results are ambiguous due to contradictory findings [53, 54]. 
1.2.2 Women 
Testosterone 
Sex-specific differences have been reported in the association between 
testosterone and the metabolic syndrome, with high levels of testosterone are 
shown in women and low levels of testosterone are shown in men [25, 31]. 
Although serum concentrations of testosterone seem to be a risk factor in 
women with regard to the metabolic syndrome, the association between 
testosterone levels and cardiovascular disease is somewhat more complicated 
[55]. The increase of CVD-rate in women with Poly Cystic Ovary Syndrome 
has not been as consistent as expected [56]. Recent studies show an 
association between low levels of testosterone and atherosclerotic disease in 
women [57-60], raising the possibility that testosterone may have beneficial 
effects on the heart or suggesting a U-shaped association with suboptimal 
effects at both extremes. 
Estradiol 
Levels of serum estradiol decrease dramatically during and after menopause. 
This decrease, combined with a large increase in the risk of CVD in women 
after menopause [61] has been the basis for the theory that estradiol might be 
protective against CVD in women. Randomized trials with estradiol have 
shown that estradiol has beneficial effects on the lipid status [62]. Among 
women near menopause enrolled in the SWAN Study, lower estradiol levels 
were associated with poorer arterial health as reflected by larger carotid 
artery interadventitial diameter [61]. In the Women’s Health Initiative (WHI) 
the clinical trial of estrogen-only treatment found a reduction in coronary 
artery disease in women aged 50 to 59, but no difference in coronary artery 
Sex hormones and cardiovascular risk in men and women 
10 
show that in both men and women low concentration of SHBG predicted 
type 2 diabetes mellitus [51]. The paper also reported that genetic variants 
associated with lower levels of SHBG production could also predict diabetes. 
The same observation was made in another cohort of only men, where 
SHBG, but not testosterone, predicted type 2 diabetes [52]. These results 
combined with the presence of membranous receptors for SHBG indicate 
that this globulin plays a more active role in the modulation of sex-hormone 
effects and in glucose metabolism in general. Moreover, a recent study in 
post-menopausal women has shown an association between SHBG and the 
incidence of hypertension [50]. Taken together, these findings suggest an 
important role for SHBG as a predictor of cardiovascular disease. Only a few 
studies have investigated the predictive value of SHBG for CVD-risk, and 
the results are ambiguous due to contradictory findings [53, 54]. 
1.2.2 Women 
Testosterone 
Sex-specific differences have been reported in the association between 
testosterone and the metabolic syndrome, with high levels of testosterone are 
shown in women and low levels of testosterone are shown in men [25, 31]. 
Although serum concentrations of testosterone seem to be a risk factor in 
women with regard to the metabolic syndrome, the association between 
testosterone levels and cardiovascular disease is somewhat more complicated 
[55]. The increase of CVD-rate in women with Poly Cystic Ovary Syndrome 
has not been as consistent as expected [56]. Recent studies show an 
association between low levels of testosterone and atherosclerotic disease in 
women [57-60], raising the possibility that testosterone may have beneficial 
effects on the heart or suggesting a U-shaped association with suboptimal 
effects at both extremes. 
Estradiol 
Levels of serum estradiol decrease dramatically during and after menopause. 
This decrease, combined with a large increase in the risk of CVD in women 
after menopause [61] has been the basis for the theory that estradiol might be 
protective against CVD in women. Randomized trials with estradiol have 
shown that estradiol has beneficial effects on the lipid status [62]. Among 
women near menopause enrolled in the SWAN Study, lower estradiol levels 
were associated with poorer arterial health as reflected by larger carotid 
artery interadventitial diameter [61]. In the Women’s Health Initiative (WHI) 
the clinical trial of estrogen-only treatment found a reduction in coronary 
artery disease in women aged 50 to 59, but no difference in coronary artery 
Bledar Daka 
11 
disease in the entire group of women aged 50 to 79 who were, on average, 
12.5 years postmenopausal [7]. For treatment with estrogen plus progestin, 
the WHI found no benefit for coronary artery disease overall, but a non-
significant reduction in rates for women within 10 years of menopause [63]. 
However, stroke events were more frequent in the intervention arm [64] 
suggesting different effects in the cerebrovascular diseases and in coronary 
disease. A change in the functional response of estrogen receptors after 
menopause can be the reason for the differing action of estradiol in aged 
women. The Three-City study [6], a French cohort of women >65 years of 
age, found an association between high levels of endogenous estradiol and 
higher risk for CVD in women who did not use exogenous hormones, with 
stroke being the most common event. Thus, emerging evidence suggests that 
estrogen associations with CVD may change with age for women without 
exogenous hormone exposure so that a protective association early in 
menopause gives way to increased risk associated with changes in arterial 
architecture. 
Sex hormone-binding globulin 
In similarity with the effects seen in men, low levels of SHBG predict 
diabetes, and in postmenopausal women, low levels have been associated 
with higher incidence of hypertension[50, 51]. However, studies regarding 
the association between SHBG levels and risk of CVD morbidity and 
mortality are still lacking. 
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2 AIMS 
2.1 General Aims 
The general aim of this thesis was to explore the association between sex 
hormones and high blood pressure in men and women, and to investigate 
their further role in the development of cardiovascular disease. Moreover, 
this thesis aims to investigate differences in levels of sex hormones and their 
specific effects in men and women, and whether these differences might 
partially explain the differences in cardiovascular risk between men and 
women. 
2.2 Specific aims 
1. To investigate mechanisms that control the concentrations of SHBG. 
2. To investigate the associations between sex hormones and high blood 
pressure in men and women. 
3. To investigate testosterone as a risk factor for cardiovascular disease in 
men and women, and to explore the modifying effect of type 2 diabetes on 
this outcome. 
4. To investigate the risk of cardiovascular disease associated with 
concentrations of estradiol in men and women with or without type 2 
diabetes. 
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3 SUBJECTS AND METHODS 
3.1 Cohorts in the Skaraborg project 
The Skaraborg Hypertension Project 
The Skaraborg Hypertension Project was launched in 1977 in the county of 
Skaraborg as a 5-year trial to improve blood pressure control, and to reduce 
the risk of acute myocardial infarction (AMI) and acute stroke in the 
community[65]. The prognosis of hypertension based on participants in the 
program was evaluated by follow-up through 1987[66]. About half of the 
population lives in the countryside and the other half in urban areas and a 
high percentage are Swedish-born. Skara was one of the municipalities 
included in the project.  
The Skara Patient and Population Cohorts 
After the medical care program Skara was well prepared for further 
population-based studies on hypertension and diabetes. Thus, in 1992-1993 
all patients in primary care with these conditions were surveyed. In 1993-
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1994 a corresponding population study was conducted as an age-stratified 
random sample drawn from the population census register. Subjects aged 40 
or over were invited to the Health Care Centre for a health examination. 
Among those aged 80 or more, 100 male and 100 female subjects were 
randomly selected and invited, as were 150 male and 150 female subjects 
from each ten-year age category between 40 and 79 years. In total 1400 
subjects were invited to participate in the study and of these, 1109 (79%) 
completed the study visit[67]. 
The Vara-Skövde Cohort 
The next phase of the project was focused on the early development of high 
blood pressure and impaired glucose metabolism, in order to gain more 
insight into their potential prevention. For this purpose, it was necessary to 
study a younger population to collect more information on lifestyles and 
metabolism, and thus, the Vara-Skövde cohort was formed. Vara is a small 
municipality with approximately 16 000 inhabitants. Ninety-five per cent of 
the residents are Swedish born and many are farmers. Skövde is the largest 
town in Skaraborg, with approximately 50 000 residents, of which 90 per 
cent are Swedish born. Skövde is more urbanized than Vara and has a more 
developed infrastructure, with a hospital and a university. Compared with 
national data, the cohort has a higher mean body mass index (BMI) and a 
higher rate of subjects born in Sweden. 
From the population census register, random samples, stratified by gender 
and five-year age groups, were generated from the total number of all 
individuals between 30 and 74 years residing in each municipality. There 
were no exclusion criteria, and subjects between 30 and 50 years of age were 
intentionally over-sampled (three-fold), as compared to subjects over 50 
years. Subjects who provided written consent to participate in the study 
visited the study nurse, completed the questionnaires, and gave venous 
blood. The final Vara-Skövde cohort consisted of 1811 subjects who fulfilled 
all requirements for participation from the Vara population (81% 
participation rate) and 1005 subjects from the Skövde population (70% 
participation rate) [68]. 
All participants provided signed informed consent prior to enrolment, and 
the Regional Ethical Review Board in Gothenburg, Sweden, approved the 
study. 
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3.2 Subjects 
Paper I, II and IV 
Paper I, II. These studies were based on the Vara-Skövde cohort with 2816 
participants. All participants with valid SHBG analyses were included in the 
study. After exclusion of subjects without such analyses for SHBG, 2,782 
subjects remained.  
Paper IV 
The last study was also based on the Vara-Skövde cohort. The hormone 
assays were successful for testosterone in 2671 (95%) individuals, for 
estradiol in 2777 (99%) individuals and for SHBG in 2782 (99%) 
individuals. The associations between sex hormones and outcomes were 
analysed separately and the participants in each analyses were restricted to 
those with valid results for that specific hormone. All analyses were 
stratified by sex and age (less than 50, vs. 50 or above). 
Paper III 
This study was based on the 1109 subjects from the population survey in 
1993-1994. After excluding 64 patients with previous AMI, 1045 subjects 
remained for data analyses. Analyses were stratified for sex and diabetes 
status. 
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3.3 Procedures  
Skara (Paper III) 
After an overnight fast (10h), participants were seen by specially educated 
and trained nurses. Participants gave verbal informed consent, and the nurses 
measured body weight and height with the participants wearing light 
clothing without shoes. Blood pressure was taken in a supine position and 
venous blood samples were drawn. The study nurses collected information 
regarding medical history and on-going medication with a special focus on 
treatment for hypertension and diabetes. All participants also answered a 
questionnaire regarding smoking habits, alcohol consumption, and physical 
activity [67]. 
Vara-Skövde (Paper I, II and IV) 
Participants were seen in the morning after an overnight fast (10h) and 
signed an informed consent form before venous blood samples were drawn. 
An oral glucose tolerance test was performed with an intake of a 75 g 
standard glucose load. During the two-hour wait for the final blood drawing, 
participants filled out a validated lifestyle questionnaire [67]. Participants 
also filled out questionnaires regarding psychosocial health, stress, quality of 
life, and civil- and socioeconomic status. Approximately two weeks after the 
first visit the participants came for a second examination by the nurses. Body 
weight and height were measured while participants were wearing light 
clothing and without shoes. They also had their blood pressure taken and 
provided detailed information on medical history and on-going medication. 
Medical History 
In both cohorts, the information regarding medical history was collected at 
baseline according to predefined criteria. The variables included were acute 
myocardial infarction, angina pectoris, heart failure, acute stroke, 
intermittent claudication, diabetes mellitus, and smoking habits. 
Physical Examination 
In both cohorts, systolic and diastolic blood pressure in the right brachial 
artery was measured in a supine position after 5 minutes rest, as well as in a 
standing position after 1 minutes rest, and recorded to the nearest 2 mm Hg. 
TricuffTM for automatic adjustment of cuff size to arm circumference was 
used and heart rate was registered simultaneously with blood pressure [69]. 
A pillow supported the arm to be at heart level. Participants were weighed 
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while wearing light clothing on a calibrated scale to the nearest 0.1 kg. 
Height was measured without shoes to the nearest cm. Waist circumference 
was measured between the lowest rib margin and iliac crest and hip 
circumference at the largest circumference between waist and thighs. Waist-
hip ratio was defined as the ratio of waist to hip circumference. Both waist- 
hip ratio and waist circumference were used to estimate abdominal obesity. 
Body mass index was calculated by the body weight in kilograms divided by 
the square of the height in meters (kg/m2), and obesity was defined as body 
mass index 30 kg/m2 [70]. Waist circumference >88 cm in women and 
>102 cm in men was defined as abdominal obesity [71]. 
Laboratory Examinations 
In both cohorts, standard laboratory tests were used for serum cholesterol, 
fasting triglycerides, fasting blood glucose in Skara Cohort and fasting 
plasma glucose in Vara and Skövde Cohort, and also HbA1c for subjects 
with diabetes. Tests for blood glucose and serum triglycerides were 
performed in a non-fasting state in insulin-treated patients with diabetes, as 
fasting tests were considered unsuitable for these patients. The analyses of 
fasting blood glucose were performed using a modified glucose 
dehydrogenase method from Hemocue (Hemocue AB, Ängelholm)[72].  
Both glucose and HbA1c were analysed by the laboratory at the local 
hospital (Kärnsjukhuset, Skövde). Serum samples for further tests were 
frozen immediately at -82°C and analysed later for lipids at the Department 
of Clinical Chemistry, Skåne University Hospital, Lund. Serum insulin was 
also analysed later at the Wallenberg Laboratory (Malmö University 
Hospital), using an enzyme linked immunosorbent assay (ELISA) with 
<0.3% cross-reactivity for proinsulin using a kit from DAKO Diagnostics 
Ltd [73, 74]. Insulin resistance was estimated based on the Homeostasis 
Model Assessment of insulin resistance (HOMA-ir): fasting insulin × fasting 
blood glucose / 22.5 [74, 75]. 
Questionnaires 
In the Skara cohort, leisure time physical activity was measured based on 
four answer alternatives to the question “How physically active are you 
during your leisure time?”. The question referred to the past year and the 
answer alternatives were: 1) Sedentary leisure time: reading, watching 
television, stamp collecting or other sedentary activity; 2) Light leisure time 
physical activity: walking, cycling, or other physical activity under at least 
four hours per week; 3) Moderate leisure time physical activity: running, 
Swimming, tennis, aerobic, heavier gardening, or similar physical activity 
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during at least 2 hours a week; 4) Heavy training or competitive sport: heavy 
training or competitions in running, skiing, swimming, football, etc, which is 
performed regularly and several times a week [76]. 
Alcohol consumption was assessed by questions concerning the number of 
days during the past 30 days during which the subjects had consumed beer, 
wine, and strong liquor, respectively. Each of these questions was followed 
by questions concerning how many cans, glasses, and/or bottles that were 
normally consumed on such days. The quantity of alcohol in gram consumed 
per week was then calculated by multiplying the number of days of alcohol 
consumption by the number of grams of alcohol contained in the consumed 
alcoholic beverage [77]. 
Smoking habits were investigated by the question “Do you smoke?”. The 
answer alternatives were: 1) No, I have never smoked; 2) No, I have smoked 
but have given it up; 3) Yes, I smoke. 
In the Vara-Skövde cohort, leisure time physical activity, alcohol 
consumption, and smoking were measured by the same questionnaire as that 
utilized in the Skara studies. 
Educational level was assessed by a question with 10 alternatives ranging 
from primary school to PhD-exams. General self-rated health was defined 
based on five answer alternatives (from “very good” to “very poor”) to the 
question “How would you rate your current health status in general?”[78] 
Diagnostic procedures 
In the Skara cohort, subjects without known hypertension were followed up 
with two further blood pressure measurements (1-2 weeks between each 
measurement) if the initial diastolic blood pressure was 90 mmHg. In 
accordance with national and international guidelines at the time, all three 
DBP had to be at least 90 mmHg, for a new diagnosis of hypertension to be 
confirmed[79]. 
In subjects without a diagnosis of diabetes, further examinations of fasting 
blood glucose were performed (1-2 weeks between measurement) if the 
initial fasting glucose value was >5.5 mmol/L. Diagnosis of diabetes was 
confirmed after two fasting blood glucose values of 6.7 mmol/L. If the 
second fasting blood glucose test showed a value between 5.6 and 6.6 
mmol/L, an oral glucose tolerance test was performed [80], and if the 2-h 
glucose value was 11.1 mmol/L, a diagnosis of diabetes was confirmed. 
Differentiation between type 1 and type 2 diabetes was based on clinical 
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criteria: i.e., age at onset, body weight, symptoms at initial stage, tendency of 
ketosis, the need for early insulin treatment, and in some cases C- peptide. 
Vara-Skövde (Paper II-IV) 
If the initial diastolic blood pressure was 90 mmHg or the initial systolic 
blood pressure was 140, in accordance with international standards [81, 
82], subjects without a diagnosis of hypertension were followed up with two 
further blood pressure measurements (1-2 weeks between each 
measurement) All three consecutive measurements of the diastolic blood 
pressure had to be 90 mmHg and/or the systolic blood pressures had to be 
140 mmHg to confirm the diagnosis of hypertension. 
Diagnosis of diabetes was confirmed after two fasting plasma glucose values 
of 7.0 mmol/L (1-2 weeks between measurements), or after one 2-h plasma 
glucose value of 11.1 mmol/L in an oral glucose tolerance test [83]. 
Differentiation between type 1 and type 2 diabetes was based on clinical 
criteria: i.e. age at onset, weight, symptoms at initial stage, tendency of 
ketosis, treatment, and in some cases C-peptide.  
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3.4 Measurements of sex hormones concentrations 
In both cohorts, total testosterone was analysed according to UniCelTM  DxI 
800 Beckman Access ® Immunoassay System Main Instrument DxI-1 in 
Malmö (Skåne University Hospital) [84]. The technique is fair in the 
estimation of testosterone levels in men [85] but poor regarding the 
estimation of testosterone in women [86]. In order to estimate the 
bioavailable fraction of testosterone and estradiol, in the Vara and Skövde 
cohorts, SHBG and estradiol were measured at Unilabs at Skaraborg 
Hospital in Skövde with results expressed in nmol/L [84]. In 19 cases with 
SHBG levels reported to be higher than 180 nmol/L but not further specified, 
we assumed them to be 180 nmol/L. We calculated the free testosterone (FT) 
according to previous studies [87, 88]. The measurements of SHBG and 
estradiol in the Skara cohort were computed later using an Electro-Chemio-
Luminiscence-Immunoassay technique[89].  
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3.5 Outcomes  
Paper I  
The outcome in the paper I is the concentration of SHBG. The measurements 
of SHBG in the Vara and Skövde cohort were performed according to 
validated methods [89, 90]. 
Paper II 
Definition: In adults hypertension is defined as a systolic and/or a diastolic 
blood pressure measurement consistently higher than 139 mmHg systolic
and/or higher than 89 mmHg diastolic[91]. Recent international hypertension 
guidelines have also created categories below the hypertensive range to 
indicate a continuum of risk with higher blood pressures in the normal range 
[92-94]. In order to avoid misclassifying, a trained nurse performed repeated 
measurements of blood pressure. In our cohort the diagnosis of hypertension 
was based on clinical information regarding patients already diagnosed and 
under treatment and on three consecutive measurements if the blood pressure 
was higher than 140/90. Each measurement of blood pressure included two 
separate measurements within 1 minute after 5 minutes of rest. 
Figure 6. Definition of hypertension according to JNC7. 
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Paper III 
Definition: In the current definition [95], AMI is defined if one of the 
following criteria satisfies the diagnosis for an acute, evolving or recent MI: 
1) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-
MB) of biochemical markers of myocardial necrosis with at least one of the 
following: a) ischemic symptoms 
b) development of pathologic Q waves on the ECG;  
c) ECG changes indicative of ischemia (ST segment 
elevation or depression); or  
d) coronary artery intervention (e.g., coronary angio-plasty).  
2) Pathologic findings of an acute MI 
According to those diagnostic criteria all such events were identified by 
record linkage with the Swedish Cause of Death and Hospital Discharge 
Registers, which is a valid alternative to revised hospital discharge and death 
certificates [96, 97]. The outcomes considered in this study were nonfatal 
and fatal events of AMI (ICD-8 and -9: 410; ICD-10: I21)[98]. All 
participants were followed from the baseline examination until a first 
cardiovascular event or death, or otherwise until December 31, 2011. 
Paper IV 
The outcomes investigated in this study were AMI, Stroke and CVD. CVD 
was defined when at least one of the events was present: AMI, Stroke, 
coronary heart disease, cardiac heart failure or atrial fibrillation.  
According to WHO [99] stroke is defined as a neurological deficit of 
cerebrovascular cause that persists beyond 24 hours or is interrupted by 
death within 24 hours. Stroke was defined as nonfatal or fatal cerebral 
infarction or intra-cerebral haemorrhage including ICD-10 codes I61, I63 
and I64 [100]. 
Coronary artery disease is a narrowing or blockage of the arteries and vessels 
that provide oxygen and nutrients to the heart. The resulting blockage 
restricts blood flow to the heart. When the blood flow is completely cut off, 
the result is an AMI. According to this, coronary heart disease was defined 
as nonfatal myocardial infarction (ICD-10 code I21), percutaneous coronary 
intervention and/or coronary artery bypass grafting, while fatal CHD was 
defined as ICD-10 codes I21-I23, I25[98]. 
Atrial fibrillation is a supraventricular tachyarrhythmia characterized by 
uncoordinated atrial activation with consequent deterioration of atrial 
mechanical function. According to this, atrial fibrillation was defined as 
ICD-10 code I48[101]. 
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Congestive heart failure occurs when the heart is unable to provide sufficient 
pump action to maintain blood flow to meet the needs of the body, and CHF 
was defined as ICD-10 code I50 [102]. All events were retrieved by data 
linkage with the Swedish Cause of Death and Hospital Discharge Registers, 
which is a reliable validated alternative to revised hospital discharge and 
death certificates [96, 97]. All participants were followed from the baseline 
examination until a first cardiovascular event or death, or otherwise until 
December 31, 2011. 
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3.6 Statistical methods 
Paper I 
General linear models were used to investigate the differences in SHBG 
levels between subjects with type 1 diabetes, type 2 diabetes, and those 
without diabetes, respectively. The association between serum insulin levels 
and SHBG concentrations was studied with linear regression after excluding 
subjects on treatment with exogenous insulin and/or on hormonal 
replacement therapy. All statistical tests were two-sided and significance was 
accepted if p<0.05. SPSS Statistics Version 20 for Mac was used for all 
statistical calculations. 
Paper II 
The association between SHBG, sex hormones and blood pressure was 
investigated in linear regression models after exclusion of subjects treated 
with blood pressure lowering drugs. Logistic regression analyses were 
performed to estimate the association between hypertension and sex 
hormones (SHBG). Associations were expressed as regression coefficients 
(B) and odds ratios (OR), respectively, both with 95% confidence intervals 
(CI). General linear models were used to estimate differences (CI) between 
continuous variables. Theoretical multivariate models were used to estimate 
the role of possible confounders on the investigated association. All analyses 
were two-sided, and significance was accepted if p<0.05. All analyses were 
performed using SPSS Statistics for Mac. In order to evaluate the strength of 
the association for each possible risk factor for hypertension, we 
standardized the variables in consideration using the formula SV=V/SD, 
where SV is the standardized variable, V is the value of the variable and SD 
is the standard deviation. We then ranked their association with hypertension 
by the regression coefficient  in the logistic regression analyses.  
Paper III 
Schoenfeld proportional hazards were used to determine the feasibility of 
Cox regression analysis. Cox Proportional Hazards Regression was 
employed to investigate the associations between levels of sex hormones at 
baseline and outcomes. Multivariate models were used to assess interactions 
and to estimate the roles of possible confounders. Stratified analyses for 
Type 2 Diabetes Mellitus were computed to investigate possible effect 
modification by diabetes. All analyses were two-sided, and p<0.05 was used 
as level of statistical significance. All analyses were performed using SPSS 
Statistics for Mac, version 20. 
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Paper IV 
The three sex hormones (SHBG, estradiol and testosterone) were normally 
distributed in men. In women the distributions of all three sex hormones 
were highly skewed, and excluding outliers did not normalize them. 
Accordingly, log-10 transformations were calculated for these measurements 
in women. Moreover, in women, every model was adjusted for hormonal 
therapy. Kaplan-Meyer survival curves for tertiles of sex hormones for each 
sex-age group were analysed to decide the feasibility of analysis with Cox 
regressions. Cox Proportional Hazards Regression was employed to 
investigate the associations between sex hormones at baseline and outcomes. 
Theoretical multivariate models were used to assess interactions and to 
estimate the roles of possible confounders. All highly skewed covariates 
were transformed by log-10. All analyses were two-sided, and p<0.05 was 
used to assess statistical significance. Interactions were deemed significant if 
p<0.15 and factors demonstrating interaction were stratified. In the age 
group above 50, stratified analyses for diabetes were computed to investigate 
possible effect modification by diabetes. All analyses were performed using 
SPSS Statistics for Mac, version 20. 
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Bledar Daka 
4 RESULTS AND DISCUSSION 
4.1 Paper I 
Results 
Baseline characteristics of this cohort have been reported elsewhere [103]. 
Serum concentrations of SHBG were inversely associated with BMI, fasting 
plasma glucose, HOMA-IR and with serum triglycerides in men and women,
respectively (all p <0.001).  
Sex stratified analyses with General Linear Model showed that SHBG levels 
were higher in subjects with T1D than in subjects without diabetes (men: 
=15.1 nmol/l, P<0.001; women: =72.9 nmol/l, P<0.001) or those with 
T2D (men: =15.9 nmol/l, P<0.001; women: =71.1 nmol/l, P<0.001) 
(Figure 7). The difference was still statistically significant after adjustments 
for age, BMI, fasting glucose and triglycerides (p<0.001). In both men and 
women, subjects with type 2 diabetes had lower levels of SHBG compared to 
subjects without diabetes in the age-adjusted analyses. The differences 
remained after making further adjustments for BMI or triglycerides or both 
together. These differences were, however, not longer significant when 
fasting plasma glucose was included as a covariate (data not shown).  
In the linear models, we found a strong association between concentrations 
of SHBG and fasting insulin in subjects without exogenous insulin, as 
presented in Table 1. Fasting plasma insulin was significantly and inversely 
associated with SHBG concentrations independent of age, BMI and fasting 
glucose levels in both men and women. The association was stronger in 
women as it remained significant when triglycerides were also included in 
the model, whereas the association was no longer significant in men (data 
not shown). 
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Figure 7. SHBG-levels in healthy controls, Type 1 and Type 2 diabetes 
patients for both genders. General linear models were used, with the results  
adjusted for age, BMI, fasting glucose and free testosterone. 
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Discussion 
In this study it was shown that subjects with T1D had significantly higher 
levels of SHBG than subjects without diabetes or with T2D and that 
concentrations of SHBG were strongly and independently associated with 
the concentrations of fasting serum insulin. Taken together, these findings 
suggest an inhibitory effect of insulin in the production of SHBG by the 
liver. 
Our results are consistent with those from previous smaller studies [52, 104, 
105], including those with only men and with in-vitro models [19, 106]. In 
accordance with other studies, a strong association was found between 
fasting serum insulin, triglycerides and SHBG levels. Low SHBG levels 
seem to be a marker for the metabolic syndrome in both men and women. In 
subjects with type 2 diabetes, the levels of SHBG were lower than in 
subjects without diabetes, but the association became insignificant after the 
adjustment for fasting glucose levels. In our study population the association 
between SHBG and insulin was significant and inverse in both men and 
women. While strong and robust in women, the association was somewhat 
weaker in men and became non-significant after simultaneously adjusting for 
age, BMI, fasting plasma glucose and free testosterone. The substantial 
reduction in the regression coefficient of serum insulin after adjusting for 
free testosterone suggests a minor and non-significant inhibitory effect of 
insulin additional to free testosterone with regard to the control of SHBG 
production in men. However, the association remained significant and strong 
in women. In addition, the changes observed in the regression coefficient 
during adjustments for BMI and fasting plasma glucose suggest an active 
regulatory role by these variables in the control of SHBG levels. 
In conclusion, these results suggest an inhibitory effect of insulin on SHBG 
production. The effect of insulin on SHBG production is of particular 
interest, as low SHBG levels can predict the development of T2D. Although 
the mechanisms behind this phenomenon are still unknown, these results 
contribute to the understanding of the regulation of SHBG concentration. 
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4.2 Paper II 
Results 
The characteristics of the study population are presented in Table 2. In men, 
SHBG increased linearly with age, but not in women. A strong negative 
association between SHBG and BMI, fasting plasma glucose, HOMA-IR and 
TG was found in both men and women and the same was true for systolic 
and diastolic blood pressure.  
After excluding subjects under medication for hypertension (n=271 (10%)), 
linear regression analyses showed a significant association between SHBG 
and both diastolic (diastolic blood pressure: ?=-0.143 p<0.001) and systolic 
blood pressure (systolic blood pressure ?=-0.114 p<0.001). The association 
remained significant after adjusting for age, BMI, HOMA-IR, triglycerides, 
HDL and CRP (diastolic blood pressure: ?=-0.113 p<0.001; systolic blood 
pressure ?=-0.093 p=0.001). Age adjusted analyses with GLM showed that, 
in men, SHBG decreased significantly with the severity of high blood 
pressure. In women, however, the SHBG was almost constant in categories 
NT and prehypertension1-3. Hypertensive women had significantly lower 
concentrations of SHBG when compared with all other categories (p<0.001) 
(Figure 8).  
In the logistic regression analyses between quartiles of SHBG and 
hypertension in women, the odds for hypertension were higher for the lowest 
quartile (OR=4.2, p<0.001). Differences in the association were observed 
after stratifying for age (women < 50 OR=2.8, CI 1.14-7.22, p=0.025, 
women 50 OR=4.8, CI 2.61-8.88, p<0.001). For women 50years, the 
association remained significant even when the model included information 
about history of stroke and diabetes in the equation (p-trend=0.043). In men 
an association was found between quartiles of SHBG and hypertension 
(OR=2.2 p=0.007). However, this association was no longer significant after 
adjustment for BMI. 
Logistic regression with standardized age, HOMA-IR, BMI and SHBG was 
used in order to evaluate the strength of the association of these measures 
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4.2 Paper II 
Results 
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Table 2. Phenotypic characterization of sex hormone-binding globulin in a 
Swedish population of men and women. 
 Men n=1,385 
  Quartiles for SHBG p-trend 
 All Q1 Q2 Q3 Q4  
SHBG 33±14 17.8 26.7 35.1 50.8  
Age 47.8±11.8 42.2 45.6 48.8 54.4 <0.001 
BMI 26.9±3.6 28.9 27.3 26.5 24.9 <0.001 
Fasting insulin 6.7±5.2 8.9 7.0 6.2 4.9 <0.001 
Fasting glucose 5.5±1.1 5.8 5.7 5.5 5.4 <0.001 
HOMA-IR 1.7±1.6 2.3 1.8 1.5 1.1 <0.001 
Hs-CRP 2.4±5.8 3.0 2.3 1.9 3.3 0.038 
LDL 3.4±0.9 3.4 3.4 3.4 3.3 0.327 
HDL 1.2±0.3 1.1 1.2 1.2 1.3 <0.001 
Triglycerides 1.5±0.9 1.9 1.5 1.3 1.1 <0.001 
Systolic BP 123±16 126 124 123 123 <0.001 
Diastolic BP 72±10 73.8 71.7 71.8 70.6 <0.001 
T-Testosterone 14.3±4.4 11.2 13.4 15.2 17.5 <0.001 
Estradiol 127±56 125 128 124 132 0.026 
FAI 48.5±17.3 64.5 50.5 43.4 35.3 <0.001 
 Women n=1,397 
SHBG 55±31 26.2 41.1 55.6 92.6  
Age 47.7±11.7 46.9 47.3 49.0 47.7 0.033 
BMI 26.8±5.3 30.1 27.2 26.5 24.9 <0.001 
Fasting insulin 6.2±4.4 8.5 6.2 5.1 4.7 <0.001 
Fasting glucose 5.3±1.1 5.7 5.4 5.1 5.1 <0.001 
HOMA-IR 1.5±1.3 2.2 1.5 1.2 1.1 <0.001 
Hs-CRP 2.7±4.6 4.1 2.5 2.2 2.3 0.097 
LDL 3.1±0.9 3.2 3.1 3.2 3.2 0.287 
HDL 1.4±0.3 1.2 1.4 1.5 1.5 <0.001 
Triglycerides 1.2±0.6 1.4 1.1 1.0 1.1 0.004 
Systolic BP 119±18 123 118 117 119 0.008 
Diastolic BP 69±10 70.0 68.4 67.8 68.2 0.007 
T-Testosterone 1.3±1.3 1.3 1.2 1.2 1.3 0.853 
Estradiol 320±396 255 328 337 363 <0.001 
FAI 3.1±5.8 5.7 2.9 2.4 1.4 <0.001 
SHBG= sex hormone-binding globulin, Q1 is the lowest quartile and Q4 is the highest. BMI= Body 
mass index, HOMA-IR= homeostatic model assessment insulin resistance, hs-CRP= high sensitive c-
reactive protein, LDL= low density lipoprotein, HDL= high density protein, BP= blood pressure, 
FAI= free androgen index. General linear models to estimate mean values and differences between 
quartiles were used. The significance was estimated with p-value <0.05.  
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Figure 8. Comparison of serum concentrations of sex hormone-binding 
globulin (y-axis) between different blood pressure categories. JNC7 blood 
pressure categories; Opt=normal optimal BP <120/80mm Hg, Nor= normal 
BP <130/85 mm Hg, Hnor= normal high BP <140/90 mm Hg, Unst= 
unstable blood pressure. Hypertension was defined as known documented 
diagnosis for high blood pressure, or by three consecutive BP reading 
140/90 mm Hg (systolic and/or diastolic). When the BP exceeded these 
limits only once or twice, the BP was categorized as unstable.  
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Discussion 
In this cross-sectional study, a strong inverse association between blood 
pressure and SHBG was observed. After the menopause, women with 
hypertension had significantly lower SHBG concentrations than women 
without hypertension. In men, we observed an inverse association between 
systolic blood pressure and SHBG. These findings were significant even 
after adjusting for major risk factors for hypertension such as age, BMI, 
diabetes and insulin resistance, indicating thus that low concentrations of 
SHBG may have independent negative effects on blood pressure control.  
The novelty of this study was a detailed analysis of the factors that could 
influence the association between SHBG and hypertension. Although there 
are some reports regarding the association between SHBG and hypertension 
in men, very few reports concern similar studies in women. In a prospective 
study in men aimed at investigating the role of sex hormones in 
hypertension, Khaw et al. [107] observed that total testosterone but not 
SHBG was associated with hypertension. However, in another cross-
sectional study in men conducted in Tromsö [108], an association between 
SHBG and systolic blood pressure was found even after adjusting for BMI 
and alcohol consumption. That study found lower concentrations of SHBG 
in hypertensive men even after adjusting for age and BMI, in accordance 
with our results in women [108]. 
Some gender differences were, however, observed in our study (Figure 6).  
In accordance with Khaw et al. [107], we found that levels of SHBG 
decreased in a linear fashion in men when the blood pressure increased. In 
contrast, the decrease in SHBG in women was observed first when they had 
developed hypertension. As the association between SHBG and hypertension 
in women was stronger over the age of 50, we suggest that these gender 
differences can at least in part be attributable to the effect of menopause in 
women. Total testosterone but not free testosterone was associated with 
hypertension in our population. We cannot confirm the vasodilatative effects 
of free testosterone that were shown by Webb et al [32]. A recent study has 
shown that SHBG but not testosterone is associated with increasing blood 
pressure. [109]. Lakshman et al. [52] speculate that a modulatory effect of 
SHBG exists that enhances the effects of testosterone. It must be emphasized 
that in a small study of men with hypertension, a strong association was 
found between SHBG and renin, which may be another pathway for direct 
effects of SHBG on the control of blood pressure [110]. Whether this 
association occurs in the blood vessel and whether it influences the blood 
pressure would need to be confirmed by studies utilizing a different design.  
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In accordance with previous studies, we found a positive linear association 
between SHBG and age in men, while in women the association was inverse 
before 50 years of age [111, 112]. The mechanisms underlying this gender 
duality are not fully understood, but it may be speculated that the decrease in 
testosterone levels is a possible factor. However, this effect does not seem to 
be a determinant of increasing SHBG concentrations in aging men according 
to De Ronde et al [50].  
In conclusion, these results show a strong association between SHBG and 
blood pressure independent of the components of metabolic syndrome and 
inflammation. This association might be explained by a direct effect of 
SHBG in endothelial cells through the receptor for SHBG. Confirmation of 
these results by others may lead to the emergence of new opportunities for 
the development of therapies for lowering blood pressure. 
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4.3 Paper 3 
Results 
The characteristics of the population at baseline are presented in Table 1 
Appendix 3. Men had significantly higher diastolic blood pressure and 
Homa-ir than women, while their prevalence of hypertension, type 2 
diabetes, smoking, and AMI was non-significantly higher than in women at 
baseline. Men with type 2 diabetes had significantly lower testosterone 
concentrations but no differences in the levels of SHBG were observed at 
baseline. In both men and women, the baseline prevalence of hypertension 
and previous AMI was higher in subjects with type 2 diabetes. However, 
there were fewer smokers among subjects with diabetes. 
The mean follow-up time was 14.1? 5.3 years. During that period 74 AMI 
events occurred in men, and 58 occurred in women. The event rate in the 
whole population was 10.3 per 1000 person years in men and 6.9 per 1000 
person years in women. Of all the events, 10 AMIs in men and 9 in women 
occurred in people with diabetes. The event rate in subjects with type 2 
diabetes was 13.8 per 1000 person years in men and 13.3 in women. Kaplan-
Meyer analyses in men (Figure 9) showed that persons in the highest quartile 
of testosterone had a tendency towards better survival in the total cohort, 
while analyses stratified for type 2 diabetes showed a significantly lower rate 
of AMI in the highest quartile of testosterone compared with the three lowest 
quartiles in men with type 2 diabetes. Although a similar tendency towards 
better survival in the highest testosterone quartile was observed in men 
without diabetes, the findings in that group were not statistically significant. 
Cox models were used to evaluate the association of concentrations of 
testosterone at baseline with AMI. In the model including all men regardless 
of diabetes status, the association between testosterone and AMI was 
marginally significant in the age-adjusted analysis (HR=0.950 95%CI 0.90-
1.00, p=0.050). When men with type 2 diabetes were analysed separately, a 
strong association was found in the age-adjusted model, which was further 
strengthened in the fully adjusted model (HR=0.754 95% CI 0.61-0.92 
p=0.006). Models using free testosterone showed similar results (Table 3). 
An interaction term assessing the relationship between testosterone and type 
2 diabetes was marginally significant (p=0.051). 
In women, trends were similar, although the results were generally not 
statistically significant. One model assessing the relationship between free 
testosterone and AMI in all women with full covariate adjustment was 
marginally significant (HR=0.722, 95% CI 0.52-1.00, p=0.046) (Appendix 3) 
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Figure 9. Kaplan-Meyers curves showing differences in survival between 
subjects in the highest quartile of serum testosterone (green) and the other 
three quartiles combined (red). Data stratified by sex (above), and in men 
also by diabetes status (below).  
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Table 3. Cox regressions analyses to investigate the association between 
testosterone and AMI.  
 Men Women 
 HR CI p HR CI P 
T-T All subjects      
 Adjusted for age 
 0.950 0.90-1.00 0.050 0.720 0.45-1.12 0.142 
 Adjusted for age, estradiol and SHBG 
 0.954 0.89-1.02 0.187 0.702 0.45-1.10 0.120 
 Adjusted for age, WHR, smoking, physical activities, LDL, SBP 
 0.949 0.90-1.00 0.069 0.696 0.45-1.08 0.104 
 Adjusted for age, WHR, smoking, physical activities, LDL, SBP, SHBG, 
estradiol 
 0.936 0.87-1.01 0.082 0.655 0.42-1.02 0.063 
 Subjects with type 2 diabetes 
 Adjusted for age 
 0.828 0.71-0.97 0.022 0.759 0.24-2.39 0.638 
 Adjusted for age, estradiol and SHBG 
 0.783 0.64-0.95 0.015 0.757 0.22-2.67 0.665 
 Adjusted for age, WHR, smoking, physical activities, LDL, SBP 
 0.754 0.61-0.92 0.006 0.647 0.18-2.28 0.498 
 Adjusted for age, WHR, smoking, physical activities, LDL, SBP, SHBG, 
estradiol 
 0.698 0.52-0.93 0.016 0.715 0.18-2.91 0.639 
HR= hazard ratio by 1 mmol/L-change in total testosterone concentration and by 
0.01 mmol/L change in free testosterone. CI= 95% of confidence interval. T-T= 
total testosterone, WHR=waist hip ration, LDL= low density lipoprotein, SBP= 
Systolic blood pressure, SHBG= sex hormone-binding globulin. 
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Discussion 
In this study, a strong and independent association between concentrations of 
testosterone and AMI was observed in men with type 2 diabetes. There was 
also a trend of an inverse association between serum testosterone and AMI in 
the cohort overall. The association in men was stronger than the association 
in women, and it remained significant after adjustment for age. The 
association was strongest among men with type 2 diabetes, where it 
remained significant after adjustment for age and factors within the 
metabolic syndrome. Previous studies in elderly men have shown an 
association between low levels of testosterone and higher risk for CVD [35, 
113]; however, prospective studies in younger men are lacking. The 
cardiovascular impact of low testosterone in this group might be difficult to 
detect because of the low event rate, but another explanation might be that 
levels of testosterone are more important in aged blood vessels. In fact, in 
our study, the major impact of testosterone was observed among subjects 
with type 2 diabetes where early vascular aging is observed [40].  
Low testosterone concentrations have previously been associated with the 
metabolic syndrome [114], and there is evidence supporting an inverse 
relationship between testosterone levels and the risk of developing type 2 
diabetes and obesity [114]. These variables were considered in the 
multivariate analyses. However, the inverse relationship between 
testosterone and incident AMI in men with T2DM remained significant after 
the adjustment for age and metabolic risk factors, suggesting that other 
mechanisms may be involved. One possibility is an effect on the coronary 
perfusion through actions on the artery wall. Fukui et al have reported that 
low concentrations of endogenous androgens were associated with increased 
artery stiffness in men with type 2 diabetes [115]. A similar result was 
reported by Akishita et al. [29] in a study of the association between 
endothelial function and testosterone levels. Moreover, Web et al [32] have 
shown a vasoactive effect of testosterone in men with coronary disease, 
supporting the idea that testosterone might have an independent 
vasoprotective effect. 
In the present study, we found that in women, free testosterone had a greater 
impact on the risk of AMI than total testosterone. This may be an artefact of 
the laboratory methods used.  
In conclusion, the measurement of testosterone in men with type 2 diabetes 
may help in the assessment of their cardiovascular risk. Larger studies 
estimating the effects of low testosterone levels in men with diabetes in 
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4.4 Paper 4 
Results 
Baseline characteristics and events registered during 8.1±1.1 years follow up 
for men and women are presented in Table 4. In men aged 50 years and 
older, there was a positive relationship between estradiol and stroke events. 
This association was independent of age, WHR, alcohol intake, smoking, 
hypertension, cholesterol, HDL-cholesterol, Hs-CRP and physical activity 
(HR=1.20 CI 1.08-1.32). This association was similar in men with and 
without diabetes. No significant associations were found between estradiol 
concentrations and AMI or CVD in men. Stratified analyses for sex and 
diabetes were conducted to evaluate the association between testosterone and 
AMI (Table 5). This association was strong and significant in men with 
diabetes (HR=0.82 CI 0.69-0.98), but not in men without diabetes (HR=1.00 
CI 0.97-1.03). A similar pattern was observed for bioavailable testosterone. 
No significant associations were found between testosterone and stroke or 
CVD in men. There was also a positive association between SHBG and CVD 
in men aged 50 years and older. This association remained significant with 
adjustment for age, WHR, alcohol intake, smoking, hypertension, 
cholesterol, HDL-cholesterol, Hs-CRP and physical activity. The association 
with SHBG was not modified by diabetes. No significant associations were 
found between SHBG and AMI or stroke in men. 
In women, distributions of the levels of all 3 sex hormones were highly 
skewed. Accordingly, we transformed these measures to log10 to normalize 
the distributions. For AMI and CVD, Kaplan-Meier graphs suggested a J-
shaped relationship with testosterone. However, further analyses using log-
rank and Cox-regression with the second tertile as the reference group failed 
to substantiate these relationships. In women older than 50 years there was 
an inverse association between estradiol and incident stroke. This association 
became significant with adjustment for age, HRT, WHR, alcohol intake, 
smoking, hypertension, cholesterol, HDL-cholesterol, Hs-CRP and physical 
activity (HR=0.28 CI 0.08-0.96). An equivalent association was found 
between free estradiol and stroke in the fully adjusted model. There were no 
significant associations between estradiol levels and AMI or CVD. A 
similar, but weaker, inverse relationship was found between SHBG and 
CVD. This association was no longer significant when diabetes was included 
in the model (Table 4). Stratified analyses showed a strong association 
between SHBG and CVD in women without diabetes (HR=0.11 CI 0.02-
0.63) but no association in those with diabetes (HR=4.18 CI 0.24-71.62). 
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Table 4. Baseline characteristics of Vara and Skövde Cohort. 
 Men n=1,385 Women n=1,397 
 Mean ± SD Mean ± SD P 
Age 47.8±11.8 47.7±11.7 0.773 
BMI 26.9±3.6 26.8±5.3 0.821 
Fasting insulin 6.7±5.2 6.2±4.4 0.002 
Fasting glucose 5.5±1.1 5.3±1.1 <0.001 
HOMA-IR 1.7±1.6 1.5±1.3 <0.001 
Hs-CRP 2.4±5.8 2.7±4.6 0.090 
LDL 3.4±0.9 3.1±0.9 <0.001 
HDL 1.2±0.3 1.4±0.3 <0.001 
Triglycerides 1.5±0.9 1.2±0.6 <0.001 
Systolic BP 123±16 119±18 <0.001 
Diastolic BP 72±10 69±10 <0.001 
Hormones    
Total Testosterone 14.3±4.4 1.3±1.3 <0.001 
Estradiol 127±56 320±396 <0.001 
SHBG 33±14 55±31 <0.001 
 N/% N/%  
Hypertension 205(14.8) 202(14.7) 0.928 
Type 2 diabetes 75(5.4) 62(4.4) 0.128 
Smoking 212(15.3) 286(20.5) <0.001 
Endpoints 
AMI  47(3.4) 18(1.2) <0.001 
Stroke 27(2.0) 25(1.7) 0.749 
CVD 126(9.0) 65(4.7) <0.001 
CHD 69(5.0) 24(1.7) <0.001 
AF 59(4.3) 27(1.9) 0.001 
HF 12(0.9) 4(0.3) 0.055 
Data are means and (+-SD) or n and (%). BMI=Body mass index, HOMA-IR=homeostatic model 
assessment for insulin resistance, Hs-CRP= high sensitive c-reactive protein, LDL= low density 
lipoprotein, HDL=High density lipoprotein, BP=blood pressure, SHBG=sex hormone binding 
globulin, AMI= Acute myocardial infarction, CVD=Cardiovascular disease, CHD=coronary heart 
disease, AF=Atrial fibrillation, HF=Heart failure. More than one endpoint may occur in the same 
subject.  
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Table 5. Cox regression analyses of the association between sex hormones and 
cardiovascular outcomes in men and women, respectively. 
Men Women 
No diabetes Diabetes No diabetes Diabetes 
HR CI HR CI HR CI HR CI 
Testosterone and AMI 
Adjusted for age 
0.95 0.87-1.04 0.88 0.78-0.99 1.33 N/A 1.38 N/A 
Adjusted for age, waist hip ratio, smoking and alcohol intake 
0.98 0.89-1.08 0.87 0.75-0.99 1.19 N/A 1.14 N/A 
Adjusted as in model above +hypertension, cholesterol, HDL, CRP and PA 
1.00 0.91-1.10 0.82 0.69-0.98 1.47 N/A N/A N/A 
Estradiol and Stroke 
Adjusted for age 
1.17 1.06-1.29 1.14 
0.91-
1.44 0.40 0.11-1.45 N/A N/A 
Adjusted for age, waist hip ratio, smoking and alcohol intake 
1.16 1.05-1.27 1.41 
0.97-
2.03 0.54 0.14-2.07 N/A N/A 
Adjusted as in model above +hypertension, cholesterol, HDL, CRP and PA 
1.17 1.05-1.31 N/A N/A 0.53 0.14-2.03 N/A N/A 
Sex hormone binding globulin and CVD 
Model 1 Adjusted for age 
1.01 0.99-1.02 1.00 0.98-1.03 0.11 0.03-0.47 N/A N/A 
Adjusted for age, waist hip ratio, smoking and alcohol intake 
1.02 1.00-1.03 1.01 0.98-1.04 0.12 0.02-0.58 N/A N/A 
Adjusted as in model above +hypertension, cholesterol, HDL, CRP and PA 
1.02 1.00-1.04 1.01 0.98-1.04 0.11 0.02-0.63 N/A N/A 
HR= hazard ratio for changes in concentrations of testosterone by 1mmol/L, estradiol by 10mmol/L 
and, SHBG by 1mmol/L in men and 1 unit of logarithm in women, CI= confidence interval, HDL= 
high density lipoprotein, CRP= c-reactive protein, PA= physical activity, N/A= not applicable. 
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Discussion 
All significant associations were found solely in subjects aged 50 years and 
older. We found opposite, yet strong and independent associations between 
concentrations of estradiol and stroke in men and women. While higher 
concentrations of estradiol were protective in women, they were a risk factor 
in men. SHBG levels predicted CVD and, similarly to the findings for 
estradiol, the direction of the association was opposite by sex with higher 
concentrations of SHBG associated with risk in men and protection in 
women. We found effect modification by diabetes mellitus with low levels 
of testosterone associated with AMI in men with diabetes, but not in men 
without. Diabetes was also an effect modifier in women, as high 
concentrations of SHBG were protective in women without diabetes. 
Importantly, this protective association was lost in women with diabetes. 
Cardiovascular effects of estradiol concentrations in men have been studied 
in two population studies with opposite conclusions [44, 45]. Tivesten et al 
[45] found a strong association between high levels of estradiol and carotid 
artery intima-medial thickness. On the other hand, Arnlov at al. [44] found 
that estradiol protects against new CVD in elderly men. The thickness of 
intima media in carotid artery is more related to stroke than to coronary 
events, but is still a strong intermediate endpoint for generalized 
atherosclerosis [116]. In our study we did not find any association between 
concentrations of estradiol and CVD overall, AMI or CHD. However, we 
found a strong association between estradiol concentrations and stroke. This 
suggests differences in effects of estradiol in cerebrovascular vessels 
compared to coronary vessels. 
Previous epidemiological studies investigating the associations between 
estradiol and CVD in women have reached different results and the 
predictive value of estradiol concentrations on future cardiovascular events is 
unclear [8]. Similar to the SWAN-study we found that high levels of 
estradiol are protective in post-menopausal women [117, 118]. These 
similarities may reflect the age of the cohorts, since the ages of our cohort 
and the SWAN study were similar. In contrast, the Three-city study, which 
followed a much older population, reported increased risk [6]. These results 
suggest that there might be age differences in the effect of the estradiol, with 
estradiol seemingly protective against CVD in early menopause, but 
associated with increased risk in elderly women. This is also consistent with 
the findings of a protective effect of estrogen alone for women aged 50 to 59, 
and no increased risk with estrogen plus progestin for women within 10 
years of menopause, in the WHI clinical trials [63]. These findings are 
consistent with the possibility that low levels of estrogen sustained for a 
decade or more result in vascular changes, such as increased intima-medial 
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thickness and atheroma burden, that ultimately result in increased risk 
associated with the actions mediated by estradiol. Currently, adequate 
clinical trial or cohort data that might answer the question of whether 
initiating estrogen treatment near menopause and continuing it through 
subsequent decades is associated with reduced CVD risk is lacking. 
In this thesis an effect modification of diabetes is shown regarding the 
association between low testosterone and cardiovascular events. Specifically, 
in men aged 50 and older with type 2 diabetes, low concentrations of 
testosterone predicted AMI. This association was not found in men without 
diabetes. However, effects of testosterone in the vessels can differ depending 
on the health of the endothelium. Diabetes is associated with early vascular 
aging [40], such that the effects of low testosterone concentrations become 
harmful in the presence of endothelial dysfunction. The measurement of 
testosterone in men with diabetes may thus provide important information 
for cardiovascular risk assessment. Trials of testosterone treatment in men 
older than 50 years with diabetes may be warranted, as there is rationale for 
protection. Appropriate designs would also provide further information about 
potential mechanisms for testosterone effects on the risk of AMI. 
Recent studies have shown an association between SHBG and type 2 
diabetes. Furthermore, low concentrations of SHBG have been associated 
with hypertension and the cumulative incidence of hypertension [109, 119]. 
However, evidence regarding the association between SHBG and CVD is 
still limited, and the results have been discordant [53, 54]. In our study the 
association of SHBG with CVD was strong, and a sub-analysis showed that 
atrial fibrillation was the component with the strongest association. A 
previous study has shown a strong association between metabolic syndrome 
and atrial fibrillation[120]. To further investigate this association we 
adjusted our analysis for components of the metabolic syndrome. Even if 
concentrations of SHBG seem to predict hypertension and diabetes, the 
underlying mechanisms are still unknown. The presence of receptors of 
SHBG that modulate the effects expressed by sex-hormones has been shown 
[121]. A recent study could also show the presence of intracellular protein 
megalin that transports the complex SHBG-steroid inside the cell, 
confirming that the SHBG is not only a carrier protein but also modulates the 
effects of sex hormones [122]. In our study, the protective effect of high 
levels of SHBG was lost in women with diabetes, although this effect 
modification was not observed for estradiol. This difference in associations 
did not seem related to study power and thus suggests the need for further 
investigation of SHBG-specific mechanisms.  
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5 GENERAL DISCUSSION 
In this thesis the association between concentration of sex hormones and 
cardiovascular diseases were explored in population-based samples. In paper 
I, exploring the factors that influence concentrations of SHBG, a strong 
association between insulin levels and SHBG was found. In paper II, a 
strong and independent association between sex hormone-binding globulin 
and hypertension was found. Although the association was present in both 
men and in women, the strongest association was observed in women aged 
50 years or older, suggesting that menopause may play an important role. In 
paper III, exploring the association between testosterone and AMI, a 
significant and independent association between concentrations of 
testosterone at baseline and the incidence of AMI in the Skara population 
cohort was found only in men with type 2 diabetes. These findings were 
confirmed in men with diabetes in the Vara-Skövde Cohort in paper IV. In 
paper IV, a strong association between estradiol and stroke was found in men 
and women. A sex difference was found in this association, as high 
concentrations of estradiol in men were predictive for stroke, while they 
protected against stroke in women. Moreover, SHBG seemed to have a 
general protective effect regarding cardiovascular disease in women. In this 
respect, diabetes modified the outcome, as the protective effect was strong 
only in women without diabetes. 
Ever since the large sex-differences in cardiovascular disease observed in 
earlier epidemiological studies, sex hormone concentrations have been 
investigated as possible biological mediators of these differences. However, 
the results have been contradictory, and consensus is still lacking regarding 
the effects of these hormones in cardiovascular disease in men and women,  
and regarding the cardiovascular effect of exogenous replacement therapy of 
these hormones. It is still unknown whether the concentrations of these 
hormones are more critical in special subgroups of patients. As 
cardiovascular disease is strongly related to age, the majority of studies 
regarding the association between sex hormones and cardiovascular 
morbidity have been done in elderly cohorts. However, whether the effects 
of sex hormones are constant over time or whether they change with vascular 
aging is not known yet. These knowledge gaps provided the background for 
the subgroup analyses conducted in this thesis, in an attempt to answer these 
questions. Thus, the investigations in Paper III and IV defined men with 
diabetes as a group of patients where the levels of testosterone were critical 
for the risk of AMI. In both cohorts the relative risk for AMI decreased with 
increasing concentrations of endogenous testosterone at baseline, suggesting 
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a protective role of testosterone in men with type 2 diabetes, albeit a similar 
effect observed in men without type 2 diabetes was not significant. The 
reason why the observation was seen only in men with diabetes, and why 
only for AMI is currently unknown but deserves further investigation. Type 
2 diabetes has been associated with an early aging of the vascular wall [40]. 
In the aged endothelium, a rapid decrease in sex hormones may cause a 
dysfunction resulting in increasing coagulability. Observations in intima 
media thickness in men with diabetes have shown a strong relationship 
between low levels of testosterone and the thickness of the intima media 
[123]. This observation suggests a protective effect of testosterone[123], 
which may be mediated by an effect of testosterone on insulin resistance 
[124, 125], on modulation of inflammation [126] and on the concentrations 
of serum lipids [127, 128]. In contrast with these positive effects of 
testosterone on improving health, a recent observational study in the US 
showed that hypogonadal men on testosterone replacement therapy had a 
higher incidence of cardiovascular events than controls[129]. The 
retrospective design of the study, however, could not address possible 
selection bias, as individuals with a higher cardiovascular risk might have 
been more likely to be treated with testosterone. Since the results of this 
thesis are in accordance with previous studies showing the protective effects 
of testosterone, it remains to be explored whether the use of testosterone in 
men with diabetes improves the prognosis for cardiovascular disease in this 
group of patients. Results of prior observational studies of the association 
between estradiol and cardiovascular events have been contradictory. 
Although studies of stroke risk in women in peri-menopause have observed a 
protective role of estradiol, studies in women aged 70 or older have shown a 
deleterious effect of estradiol. It seems that aging has a modifying effect on 
the association between estradiol and cardiovascular disease in women. The 
cohort investigated in this thesis was younger, and events in subjects 
younger than 50 at base line were scarce. However, in both men and women 
a strong association between stroke events and estradiol levels was observed. 
The results show a sex-duality in this association, as high concentrations of 
estradiol were protective in women, but deleterious in men. Estradiol levels 
in men reflect an increase of aromatase activity with aging and obesity. High 
age and obesity are two known risk factors for hypertension and stroke; 
however, the association in men was still significant after adjustments for 
both these factors. These findings are in accordance with other studies that 
found a strong association between concentrations of estradiol and an 
increase in the intima media thickness in men [44, 45]. Estradiol seems thus 
to have negative effects on the cardiovascular risk and endothelium function 
in men.  
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In the Vara-Skövde cohort SHBG levels were associated with higher risk for 
cardiovascular disease. While low concentrations of SHBG have been 
associated with higher risk for cardiovascular disease in both men and 
women, a sex duality was observed in our cohort. Thus, high concentrations 
in women were protective. However, this was confirmed only in women 
without diabetes suggesting that the protective effect in women is lost when 
they are affected with type 2 diabetes. Type 2 diabetes in women can have a 
modifying effect on the protective role of sex hormones that could explain at 
least partially the loss of protection regarding AMI observed in women with 
type 2 diabetes[130]. The young population and the low event rates might 
implicate low statistical power, and a type 2 error cannot be excluded.  
In contrast, in paper 2 a strong association between SHBG and blood 
pressure was found in both men and women. The association had the same 
direction in both men and women, and no sex duality was observed in the 
association between SHBG and blood pressure. While the concentrations of 
SHBG predicted diabetes in both men and women in two different cohorts 
[51, 52], the mechanisms behind this association are unknown. Experimental 
studies have shown that the presence of membranous receptors for SHBG is 
capable of altering concentrations of c-AMP when bound to their ligands. 
The hypothesis is that SHBG essentially modulates the effects of sex 
hormones by influencing their intracellular transport [122]. These 
physiologic mechanisms of SHBG are still to be understood in detail, but 
could potentially explain how SHBG can predict type 2 diabetes and 
hypertension. These findings, however, are in accordance with the findings 
in the paper 4 and the higher risk for cardiovascular disease shown in women 
with lower concentrations of SHBG. The association between high levels of 
SHBG and higher risk of CVD in men needs further investigation, as it was 
unexpected. As SHBG is related to cardiovascular risk and the effect and 
function of sex hormones, it would be  important to know which 
mechanisms control the concentrations of SHBG. Genetic variants have been 
associated with different concentrations of SHBG [131, 132]. Hormonal 
factors have also been associated with higher concentrations of SHBG[15-
18]. Moreover, obesity is associated with low levels of SHBG and anorexia 
is associated with higher levels [15-18]. Whether glucose or insulin controls 
levels of SHBG has been an area of debate. The findings presented in paper I 
indicated, however, that endogenous insulin is independently associated with 
concentrations of SHBG, providing further information regarding 
mechanisms of control of SHBG concentrations. 
In conclusion, concentrations of sex hormones predicted cardiovascular 
morbidity in both men and women, albeit differently according to sex. While 
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testosterone was protective in men, estradiol and SHBG were protective in 
women. Correspondingly, the effects of estradiol in men seem negative 
while the effects of testosterone in women were uncertain. Thus, in each sex 
the characteristic hormone supports health. Diabetes also modified the 
association between concentration of sex hormones and CVD in both sexes. 
These modifications might explain at least partially the loss of the 
cardiovascular protection in women when they contract diabetes. There may 
be a potential for replacement therapy using testosterone in men with 
diabetes. 
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6 METHODOLOGICAL CONSIDERATIONS  
General considerations 
This thesis was based on large population samples with high participation 
rates. The participation rate was 79% in the Skara population cohort and 
76% in the Vara and Skövde cohort. This high participation rate combined 
with register based random selection enhances the representativeness of the 
study sample. However, a minor selection bias is possible as nonparticipants 
tend to have different characteristics and generally have a higher burden of 
cardiovascular comorbidity [133]. Comprehensive characterization of the 
cohorts regarding health status, lifestyle factors and biological markers at 
baseline provided the opportunity to investigate the associations between sex 
hormones and cardiovascular outcomes as well as possible confounders of 
these associations. The sample size provided adequate power to evaluate 
clinically meaningful associations. Although these analyses are post-hoc, a 
stratified design for subjects older and younger than 50 years of age in Vara-
Skövde cohort and for type 2 diabetes was planed from the beginning in 
order to avoid accidental findings and to investigate an effect modifying of 
diabetes in both men and women. It should also be acknowledged that the 
cross-sectional design of the study in papers I and II do not allow the 
establishment of causality regarding the association between SHBG and 
insulin and between SHBG and hypertension. 
Outcomes 
The outcome in Paper I was SHBG. The method used is valid [84]. The 
measurement of SHBG concentrations were successful in 2782 subjects and 
permitted further analyses for the original hypothesis. 
The outcome in Paper II was hypertension and blood pressure. The 
measurement of this outcome was based on repeated measurements. The 
diagnosis of hypertension was based on international criteria [134] only if 
the subject had 3 repetitive blood pressure measurements 140/90 mm Hg 
and/or already was diagnosed and treated for hypertension. 
The outcome in Paper III was acute myocardial infarction. The outcome was 
defined using record linkage with the Swedish national mortality register and 
the National inpatient register. The method has been validated previously 
[98] and the use of register data regarding this outcome is common.  
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In Paper IV, 3 outcomes were considered: AMI, CVD and Stroke. While the 
use of AMI based on registries has been validated in previous publications 
[98], no recent publications appear to exist regarding the validity of the use 
of registries regarding stroke diagnosis. Two different studies in 1993 and 
2000 [135, 136] showed an unsatisfactory correlation between the diagnosis 
stroke in the registers and the validation by revised hospital discharges. 
However, better diagnostic instruments and their frequent use in the last 
decade should have improved the quality of the register. The majority of 
register-based studies use the Swedish national mortality register and the 
National inpatient register [137-140] and we also chose to do so. Further 
studies to elucidate the validity in using these registers are needed. 
In Papers III and IV the number of the events was lower than expected in the 
planning phase of these cohorts. The lack of events was attributable to the 
decrease of the incidence in the cardiovascular disease in the last decades 
[141]. The fact that these studies were based on a small number of events 
may have increased the risk for type two error. Nevertheless, there is a risk 
of overestimating the effects with Cox regression analyses on small samples 
[142]. Accordingly, the analyses of sex hormones were done in two cohorts 
and the results were compared between cohorts for the assessment of their 
consistency.  
Exposure 
Blood samples were collected in the morning, thereby avoiding influences of 
circadian variations in the hormonal concentrations. The diagnosis of 
diabetes was accurate and in accordance with WHO recommendation [143].  
A potential weakness of this study is the lack of information with regard to 
menopausal status. Still, the use of 50 years as a cut-off point for menopause 
is supported by findings from previous studies [144, 145]. The 
comprehensive medical history permitted identification of individuals using 
hormonal therapy and the analysis of them separately. Analyses restricted to 
the participants below the age of 50 had limited power due to the small 
number of events. Future analyses with longer follow-up in this 
subpopulation will permit investigation of the role of sex steroids in the 
development of the diseases. 
Another limitation in this thesis is the low accuracy of the measurements of 
testosterone in the low range of the distribution, which concerns especially 
women [146, 147]. Moreover there is a circadian variation of concentrations 
of sex hormones and SHBG which probably attenuates our findings [148]. 
The small number of men with type 2 diabetes in Papers III and IV is another 
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weakness in this thesis, as there is a risk of overestimating effects in 
subgroup analyses [142]. However, the consistency of these results across 
strata, and the significant findings despite the small sample size in two 
different cohorts suggest a strong association.  
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7 CONCLUSION 
7.1 General conclusions 
Strong associations between sex hormones and cardiovascular risk were 
observed in both men and women. While testosterone was protective in men, 
estradiol levels seemed protective in women. Diabetes modified the effect of 
sex hormones in both men and women. While the protective effect of 
testosterone in men for acute myocardial infarct was observable in cases with 
diabetes, the presence of diabetes in women seemed to cancel the protective 
effects of SHBG regarding CVD. These differences in the effects of sex 
hormones observed in women with diabetes can, at least partially, explain 
the elemination of the protection against acute myocardial infarction in these 
women. 
7.2 Specific conclusions 
1. There is an inverse association between SHBG and endogenous insulin, 
independent of age, BMI, and plasma glucose.  
2. There is a strong association between SHBG and blood pressure 
independent of metabolic factors in both men and women.  
3. Low concentrations of testosterone are associated with higher risk for 
AMI in men with type 2 diabetes. Although the association was present in 
men without diabetes and in women it was weaker and statistically not 
significant. 
4. Estradiol concentrations are inversely associated with the risk for stroke in 
women but are positively associated with the risk for stroke in men.  
5. A duality in the effects of SHBG was also observed. High levels of SHBG 
were protective in women, especially in those without diabetes, whereas in 
men high levels of SHBG were related to higher risk for CVD. 
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8 FUTURE PERSPECTIVES 
Apart from the physiological effects in the reproductive tissues, sex 
hormones have been associated with aging, and low levels of the 
representative sex hormone in each sex have been associated with 
deterioration of endothelial function. In Papers III and IV it was shown that 
the measurements of testosterone in men with type 2 diabetes may help in 
the assessment of their cardiovascular risk. These results suggest a potential 
benefit of testosterone replacement therapy in men with diabetes, although 
this needs to be replicated in other populations and tested in randomized 
controlled trials. 
Together with the initiation of a 10-year follow-up of the Vara-Skövde 
cohort, these cohorts provide excellent opportunities for longitudinal studies. 
With this platform, it will be possible to study the factors that influence 
changes in sex hormones. Moreover, it will be possible to study how these 
changes in sex hormones influence the risk of cardiovascular disease and 
quality of life. Finally, the follow up of these cohorts as they progress from 
middle to older age will provide the opportunity to observe whether age is a 
modifying factor in the association between sex hormones and 
cardiovascular disease. 
In Paper IV, stroke events were less frequent in women with high 
endogenous estradiol. These findings are in accordance with findings in the 
SWAN study, suggesting that endogenous estradiol has a protective effect in 
women. Our results, taken in context of findings for CVD from other studies 
such as WHI, support the possibility of different effects with age of estradiol 
in the menopause, as estradiol may be protective in the beginning of the 
menopause but harmful in the later menopause. The repeated measurement 
of estradiol levels in this population should provide a good possibility for the 
investigation of this hypothesis. 
In Paper II, an independent association of SHBG with blood pressure levels 
was observed. These findings are in accordance with other observations 
suggesting a more active role for sex-hormone binding globulin in the action 
of sex hormones. The confirmation of these observations by other studies 
might open up a new field for the development of therapies for lowering 
blood pressure. In Paper I an inhibitory effect of insulin on the SHBG 
production was found. These results will contribute to the understanding of 
the regulation of SHBG concentration. 
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Finally, this study revealed large differences in how sex hormone 
concentrations are related to cardiovascular disease and to risk factors in men 
and women, suggesting that sex hormones have a key position in the 
understanding of the differences in the cardiovascular disease in men and 
women. More research concerning the endothelial effects of sex hormones 
may have an important impact on future cardiovascular risk assessment and 
treatment recommendations.  
 
Sex hormones and cardiovascular risk in men and women 
54 
Finally, this study revealed large differences in how sex hormone 
concentrations are related to cardiovascular disease and to risk factors in men 
and women, suggesting that sex hormones have a key position in the 
understanding of the differences in the cardiovascular disease in men and 
women. More research concerning the endothelial effects of sex hormones 
may have an important impact on future cardiovascular risk assessment and 
treatment recommendations.  
 
 55 
ACKNOWLEDGEMENT 
My sincere gratitude to all those who helped me in this project: without you 
this thesis wouldn’t have come to a completion. I want to thank you all, 
including those not mentioned here by name. My deepest gratitude goes to all 
collaborators and participants of the study, without whom this thesis would 
not have been possible. 
Ulf Lindblad, my main supervisor, the person always believing in me and 
encouraging me. Thank you for sharing your extensive knowledge in family 
medicine and in the epidemiology of hypertension and cardiovascular 
diseases. It has been a privilege to work with you during these years. 
Thord Rosén, my co-supervisor for sharing with me your expertise in sex 
hormones in a friendly and supportive way. 
Per Anders Jansson, my co supervisor for your critical thinking and for 
generously sharing your expertise in diabetes and endothelial function. 
Robert Langer, my tutor during my research period in the US, and to the 
Department of Family Medicine-Las Vegas, thank you for your support and 
for sharing your expertise with regard to women health.  
Cecilia Björkelund and all the staff of the Department of Family Medicine at 
Gothenburg University for providing excellent conditions for scientific 
research and for friendly support. 
Lennart Råstam, my co-author in paper I, II and III, thank you for all your 
kind support and for constructive criticism. 
Charlotte Larsson, co-author in paper I, II, III, and friend, thank you for 
sharing your knowledge in a supportive and friendly way. 
Vani Dandolu, colleague and co-author in paper IV, thank you for sharing 
your knowledge and expertise with regard to women health. 
Åsa Tivesten, Robbert Eggertsen and Peter  thank you for 
constructive criticism during the half-time seminar. 
Margareta Hellgren and all teammates in the research group, but especially 
Jenny Eckner, Eva Deutsch, Maria Ericsson and Hormoz Alayar, thank you 
for your support and for sharing your ideas with me.  
Bertil Anséhn, head of Masthuggets Vårdcentral, and to all other friends and 
Colleagues there for the friendly support that I felt during all this period. 
 
55 
ACKNOWLEDGEMENT 
My sincere gratitude to all those who helped me in this project: without you 
this thesis wouldn’t have come to a completion. I want to thank you all, 
including those not mentioned here by name. My deepest gratitude goes to all 
collaborators and participants of the study, without whom this thesis would 
not have been possible. 
Ulf Lindblad, my main supervisor, the person always believing in me and 
encouraging me. Thank you for sharing your extensive knowledge in family 
medicine and in the epidemiology of hypertension and cardiovascular 
diseases. It has been a privilege to work with you during these years. 
Thord Rosén, my co-supervisor for sharing with me your expertise in sex 
hormones in a friendly and supportive way. 
Per Anders Jansson, my co supervisor for your critical thinking and for 
generously sharing your expertise in diabetes and endothelial function. 
Robert Langer, my tutor during my research period in the US, and to the 
Department of Family Medicine-Las Vegas, thank you for your support and 
for sharing your expertise with regard to women health.  
Cecilia Björkelund and all the staff of the Department of Family Medicine at 
Gothenburg University for providing excellent conditions for scientific 
research and for friendly support. 
Lennart Råstam, my co-author in paper I, II and III, thank you for all your 
kind support and for constructive criticism. 
Charlotte Larsson, co-author in paper I, II, III, and friend, thank you for 
sharing your knowledge in a supportive and friendly way. 
Vani Dandolu, colleague and co-author in paper IV, thank you for sharing 
your knowledge and expertise with regard to women health. 
Åsa Tivesten, Robbert Eggertsen and Peter  thank you for 
constructive criticism during the half-time seminar. 
Margareta Hellgren and all teammates in the research group, but especially 
Jenny Eckner, Eva Deutsch, Maria Ericsson and Hormoz Alayar, thank you 
for your support and for sharing your ideas with me.  
Bertil Anséhn, head of Masthuggets Vårdcentral, and to all other friends and 
Colleagues there for the friendly support that I felt during all this period. 
LindqvistLindqvist
Sex hormones and cardiovascular risk in men and women 
56 
To all bodies and funds that supported my research economically; The 
University of Gothenburg; Region Västra Götaland, The Local Research and 
Development Board for Gothenburg and Södra Bohuslän, Skaraborg 
Institute, National Research School in General Practice, The Göteborg 
Medical Society, and The Swedish Society of Medicine.  
Rezarta, my wife, thank you for believing in me even when I didn’t. 
Jona and Albin, my children, thank you for bringing immense love and joy to 
my life. 
My mother Fadilet and my Aunt Violeta, for planting interests in science and 
critical thinking on me since childhood. 
Sex hormones and cardiovascular risk in men and women 
56 
To all bodies and funds that supported my research economically; The 
University of Gothenburg; Region Västra Götaland, The Local Research and 
Development Board for Gothenburg and Södra Bohuslän, Skaraborg 
Institute, National Research School in General Practice, The Göteborg 
Medical Society, and The Swedish Society of Medicine.  
Rezarta, my wife, thank you for believing in me even when I didn’t. 
Jona and Albin, my children, thank you for bringing immense love and joy to 
my life. 
My mother Fadilet and my Aunt Violeta, for planting interests in science and 
critical thinking on me since childhood. 
 57 
REFERENCES 
1. "Stop the global epidemic of chronic disease"--new report, 
preventing chronic diseases: a vital investment estimates 
hundreds of billions of dollars at stake. Indian J Med Sci 2005, 
59(10):463-465. 
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown 
TM, Carnethon MR, Dai S, de Simone G, Ford ES et al: Heart 
disease and stroke statistics--2011 update: a report from the 
American Heart Association. Circulation 2011, 123(4):e18-e209. 
3. Traish AM, Saad F, Feeley RJ, Guay A: The dark side of 
testosterone deficiency: III. Cardiovascular disease. J Androl 
2009, 30(5):477-494. 
4. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, 
Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL: 
Acute anti-ischemic effect of testosterone in men with coronary 
artery disease. Circulation 1999, 99(13):1666-1670. 
5. Traish AM, Saad F, Guay A: The dark side of testosterone 
deficiency: II. Type 2 diabetes and insulin resistance. J Androl 
2009, 30(1):23-32. 
6. Scarabin-Carre V, Canonico M, Brailly-Tabard S, Trabado S, 
Ducimetiere P, Giroud M, Ryan J, Helmer C, Plu-Bureau G, 
Guiochon-Mantel A et al: High level of plasma estradiol as a new 
predictor of ischemic arterial disease in older postmenopausal 
women: the three-city cohort study. Journal of the American Heart 
Association 2012, 1(3):e001388. 
7. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, 
Pettinger M, Heckbert SR, Greep N, Crawford S et al: Conjugated 
equine estrogens and coronary heart disease: the Women's 
Health Initiative. Arch Intern Med 2006, 166(3):357-365. 
8. Barrett-Connor E: Menopause, atherosclerosis, and coronary 
artery disease. Current opinion in pharmacology 2013. 
9. Cleland WH, Mendelson CR, Simpson ER: Effects of aging and 
obesity on aromatase activity of human adipose cells. J Clin 
Endocrinol Metab 1985, 60(1):174-177. 
10. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, Pelletier G, 
Labrie C: Is dehydroepiandrosterone a hormone? J Endocrinol 
2005, 187(2):169-196. 
11. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I: 
Estradiol in elderly men. Aging Male 2002, 5(2):98-102. 
12. Lecomte P, Lecureuil N, Lecureuil M, Osorio Salazar C, Valat C: 
Age modulates effects of thyroid dysfunction on sex hormone 
binding globulin (SHBG) levels. Exp Clin Endocrinol Diabetes 
1995, 103(5):339-342. 
 
57 
REFERENCES 
1. "Stop the global epidemic of chronic disease"--new report, 
preventing chronic diseases: a vital investment estimates 
hundreds of billions of dollars at stake. Indian J Med Sci 2005, 
59(10):463-465. 
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown 
TM, Carnethon MR, Dai S, de Simone G, Ford ES et al: Heart 
disease and stroke statistics--2011 update: a report from the 
American Heart Association. Circulation 2011, 123(4):e18-e209. 
3. Traish AM, Saad F, Feeley RJ, Guay A: The dark side of 
testosterone deficiency: III. Cardiovascular disease. J Androl 
2009, 30(5):477-494. 
4. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, 
Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL: 
Acute anti-ischemic effect of testosterone in men with coronary 
artery disease. Circulation 1999, 99(13):1666-1670. 
5. Traish AM, Saad F, Guay A: The dark side of testosterone 
deficiency: II. Type 2 diabetes and insulin resistance. J Androl 
2009, 30(1):23-32. 
6. Scarabin-Carre V, Canonico M, Brailly-Tabard S, Trabado S, 
Ducimetiere P, Giroud M, Ryan J, Helmer C, Plu-Bureau G, 
Guiochon-Mantel A et al: High level of plasma estradiol as a new 
predictor of ischemic arterial disease in older postmenopausal 
women: the three-city cohort study. Journal of the American Heart 
Association 2012, 1(3):e001388. 
7. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, 
Pettinger M, Heckbert SR, Greep N, Crawford S et al: Conjugated 
equine estrogens and coronary heart disease: the Women's 
Health Initiative. Arch Intern Med 2006, 166(3):357-365. 
8. Barrett-Connor E: Menopause, atherosclerosis, and coronary 
artery disease. Current opinion in pharmacology 2013. 
9. Cleland WH, Mendelson CR, Simpson ER: Effects of aging and 
obesity on aromatase activity of human adipose cells. J Clin 
Endocrinol Metab 1985, 60(1):174-177. 
10. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, Pelletier G, 
Labrie C: Is dehydroepiandrosterone a hormone? J Endocrinol 
2005, 187(2):169-196. 
11. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I: 
Estradiol in elderly men. Aging Male 2002, 5(2):98-102. 
12. Lecomte P, Lecureuil N, Lecureuil M, Osorio Salazar C, Valat C: 
Age modulates effects of thyroid dysfunction on sex hormone 
binding globulin (SHBG) levels. Exp Clin Endocrinol Diabetes 
1995, 103(5):339-342. 
Sex hormones and cardiovascular risk in men and women 
58 
13. Gershagen S, Doeberl A, Jeppsson S, Rannevik G: Decreasing 
serum levels of sex hormone-binding globulin around the 
menopause and temporary relation to changing levels of ovarian 
steroids, as demonstrated in a longitudinal study. Fertil Steril 
1989, 51(4):616-621. 
14. Lecomte P, Lecureuil N, Lecureuil M, Lemonnier Y, Mariotte N, 
Valat C, Garrigue MA: Sex differences in the control of sex-
hormone-binding globulin in the elderly: role of insulin-like 
growth factor-I and insulin. Eur J Endocrinol 1998, 139(2):178-
183. 
15. Selva DM, Hammond GL: Thyroid hormones act indirectly to 
increase sex hormone-binding globulin production by liver via 
hepatocyte nuclear factor-4alpha. J Mol Endocrinol 2009, 
43(1):19-27. 
16. Cangemi R, Friedmann AJ, Holloszy JO, Fontana L: Long-term 
effects of calorie restriction on serum sex-hormone 
concentrations in men. Aging cell 2010, 9(2):236-242. 
17. Haffner SM: Sex hormone-binding protein, hyperinsulinemia, 
insulin resistance and noninsulin-dependent diabetes. Horm Res 
1996, 45(3-5):233-237. 
18. Haffner SM: Sex hormones, obesity, fat distribution, type 2 
diabetes and insulin resistance: epidemiological and clinical 
correlation. Int J Obes Relat Metab Disord 2000, 24 Suppl 2:S56-
58. 
19. Selva DM, Hogeveen KN, Innis SM, Hammond GL: 
Monosaccharide-induced lipogenesis regulates the human 
hepatic sex hormone-binding globulin gene. J Clin Invest 2007, 
117(12):3979-3987. 
20. Joseph DR: Structure, function, and regulation of androgen-
binding protein/sex hormone-binding globulin. Vitam Horm 1994, 
49:197-280. 
21. Krupenko SA, Krupenko NI, Danzo BJ: Interaction of sex 
hormone-binding globulin with plasma membranes from the rat 
epididymis and other tissues. J Steroid Biochem Mol Biol 1994, 
51(1-2):115-124. 
22. Fortunati N: Sex hormone-binding globulin: not only a transport 
protein. What news is around the corner? J Endocrinol Invest 
1999, 22(3):223-234. 
23. Laughlin GA, Barrett-Connor E: Sexual dimorphism in the 
influence of advanced aging on adrenal hormone levels: the 
Rancho Bernardo Study. J Clin Endocrinol Metab 2000, 
85(10):3561-3568. 
24. Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail 
G: Free and protein-bound plasma estradiol-17 beta during the 
menstrual cycle. J Clin Endocrinol Metab 1976, 43(2):436-445. 
Sex hormones and cardiovascular risk in men and women 
58 
13. Gershagen S, Doeberl A, Jeppsson S, Rannevik G: Decreasing 
serum levels of sex hormone-binding globulin around the 
menopause and temporary relation to changing levels of ovarian 
steroids, as demonstrated in a longitudinal study. Fertil Steril 
1989, 51(4):616-621. 
14. Lecomte P, Lecureuil N, Lecureuil M, Lemonnier Y, Mariotte N, 
Valat C, Garrigue MA: Sex differences in the control of sex-
hormone-binding globulin in the elderly: role of insulin-like 
growth factor-I and insulin. Eur J Endocrinol 1998, 139(2):178-
183. 
15. Selva DM, Hammond GL: Thyroid hormones act indirectly to 
increase sex hormone-binding globulin production by liver via 
hepatocyte nuclear factor-4alpha. J Mol Endocrinol 2009, 
43(1):19-27. 
16. Cangemi R, Friedmann AJ, Holloszy JO, Fontana L: Long-term 
effects of calorie restriction on serum sex-hormone 
concentrations in men. Aging cell 2010, 9(2):236-242. 
17. Haffner SM: Sex hormone-binding protein, hyperinsulinemia, 
insulin resistance and noninsulin-dependent diabetes. Horm Res 
1996, 45(3-5):233-237. 
18. Haffner SM: Sex hormones, obesity, fat distribution, type 2 
diabetes and insulin resistance: epidemiological and clinical 
correlation. Int J Obes Relat Metab Disord 2000, 24 Suppl 2:S56-
58. 
19. Selva DM, Hogeveen KN, Innis SM, Hammond GL: 
Monosaccharide-induced lipogenesis regulates the human 
hepatic sex hormone-binding globulin gene. J Clin Invest 2007, 
117(12):3979-3987. 
20. Joseph DR: Structure, function, and regulation of androgen-
binding protein/sex hormone-binding globulin. Vitam Horm 1994, 
49:197-280. 
21. Krupenko SA, Krupenko NI, Danzo BJ: Interaction of sex 
hormone-binding globulin with plasma membranes from the rat 
epididymis and other tissues. J Steroid Biochem Mol Biol 1994, 
51(1-2):115-124. 
22. Fortunati N: Sex hormone-binding globulin: not only a transport 
protein. What news is around the corner? J Endocrinol Invest 
1999, 22(3):223-234. 
23. Laughlin GA, Barrett-Connor E: Sexual dimorphism in the 
influence of advanced aging on adrenal hormone levels: the 
Rancho Bernardo Study. J Clin Endocrinol Metab 2000, 
85(10):3561-3568. 
24. Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail 
G: Free and protein-bound plasma estradiol-17 beta during the 
menstrual cycle. J Clin Endocrinol Metab 1976, 43(2):436-445. 
 59 
25. Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous 
sex hormones and risk of type 2 diabetes: a systematic review 
and meta-analysis. Jama 2006, 295(11):1288-1299. 
26. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen 
TP, Valkonen VP, Salonen R, Salonen JT: Testosterone and sex 
hormone-binding globulin predict the metabolic syndrome and 
diabetes in middle-aged men. Diabetes Care 2004, 27(5):1036-
1041. 
27. Basaria S: Androgen deprivation therapy, insulin resistance, and 
cardiovascular mortality: an inconvenient truth. J Androl 2008, 
29(5):534-539. 
28. Barud W, Palusinski R, Beltowski J, Wojcicka G: Inverse 
relationship between total testosterone and anti-oxidized low 
density lipoprotein antibody levels in ageing males. 
Atherosclerosis 2002, 164(2):283-288. 
29. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, 
Ouchi Y: Low testosterone level is an independent determinant of 
endothelial dysfunction in men. Hypertens Res 2007, 30(11):1029-
1034. 
30. Khaw KT, Barrett-Connor E: Blood pressure and endogenous 
testosterone in men: an inverse relationship. J Hypertens 1988, 
6(4):329-332. 
31. Laughlin GA, Barrett-Connor E, May S: Sex-specific association of 
the androgen to oestrogen ratio with adipocytokine levels in 
older adults: the Rancho Bernardo Study. Clin Endocrinol (Oxf) 
2006, 65(4):506-513. 
32. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P: 
Effects of testosterone on coronary vasomotor regulation in men 
with coronary heart disease. Circulation 1999, 100(16):1690-1696. 
33. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, 
McKinlay JB: Association of sex hormones and C-reactive protein 
levels in men. Clin Endocrinol (Oxf) 2009. 
34. Wenceslau CF, McCarthy CG, Goulopoulou S, Szasz T, NeSmith 
EG, Webb RC: Mitochondrial-derived N-formyl peptides: Novel 
links between trauma, vascular collapse and sepsis. Medical 
Hypotheses 2013, 81(4):532-535. 
35. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum 
testosterone and mortality in older men. J Clin Endocrinol Metab 
2008, 93(1):68-75. 
36. Shahani S, Braga-Basaria M, Basaria S: Androgen deprivation 
therapy in prostate cancer and metabolic risk for atherosclerosis. 
J Clin Endocrinol Metab 2008, 93(6):2042-2049. 
37. Collins L, Basaria S: Adverse effects of androgen deprivation 
therapy in men with prostate cancer: a focus on metabolic and 
 
59 
25. Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous 
sex hormones and risk of type 2 diabetes: a systematic review 
and meta-analysis. Jama 2006, 295(11):1288-1299. 
26. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen 
TP, Valkonen VP, Salonen R, Salonen JT: Testosterone and sex 
hormone-binding globulin predict the metabolic syndrome and 
diabetes in middle-aged men. Diabetes Care 2004, 27(5):1036-
1041. 
27. Basaria S: Androgen deprivation therapy, insulin resistance, and 
cardiovascular mortality: an inconvenient truth. J Androl 2008, 
29(5):534-539. 
28. Barud W, Palusinski R, Beltowski J, Wojcicka G: Inverse 
relationship between total testosterone and anti-oxidized low 
density lipoprotein antibody levels in ageing males. 
Atherosclerosis 2002, 164(2):283-288. 
29. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, 
Ouchi Y: Low testosterone level is an independent determinant of 
endothelial dysfunction in men. Hypertens Res 2007, 30(11):1029-
1034. 
30. Khaw KT, Barrett-Connor E: Blood pressure and endogenous 
testosterone in men: an inverse relationship. J Hypertens 1988, 
6(4):329-332. 
31. Laughlin GA, Barrett-Connor E, May S: Sex-specific association of 
the androgen to oestrogen ratio with adipocytokine levels in 
older adults: the Rancho Bernardo Study. Clin Endocrinol (Oxf) 
2006, 65(4):506-513. 
32. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P: 
Effects of testosterone on coronary vasomotor regulation in men 
with coronary heart disease. Circulation 1999, 100(16):1690-1696. 
33. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, 
McKinlay JB: Association of sex hormones and C-reactive protein 
levels in men. Clin Endocrinol (Oxf) 2009. 
34. Wenceslau CF, McCarthy CG, Goulopoulou S, Szasz T, NeSmith 
EG, Webb RC: Mitochondrial-derived N-formyl peptides: Novel 
links between trauma, vascular collapse and sepsis. Medical 
Hypotheses 2013, 81(4):532-535. 
35. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum 
testosterone and mortality in older men. J Clin Endocrinol Metab 
2008, 93(1):68-75. 
36. Shahani S, Braga-Basaria M, Basaria S: Androgen deprivation 
therapy in prostate cancer and metabolic risk for atherosclerosis. 
J Clin Endocrinol Metab 2008, 93(6):2042-2049. 
37. Collins L, Basaria S: Adverse effects of androgen deprivation 
therapy in men with prostate cancer: a focus on metabolic and 
Sex hormones and cardiovascular risk in men and women 
60 
cardiovascular complications. Asian journal of andrology 2012, 
14(2):222-225. 
38. Hakimian P, Blute M, Jr., Kashanian J, Chan S, Silver D, Shabsigh 
R: Metabolic and cardiovascular effects of androgen deprivation 
therapy. BJU international 2008, 102(11):1509-1514. 
39. Nilsson PM: The early vascular ageing (EVA) syndrome - How to 
define it? Lege Artis Medicinae 2010, 20(12):831-834. 
40. Nilsson PM, Boutouyrie P, Laurent S: Vascular aging: A tale of eva 
and ADAM in cardiovascular risk assessment and prevention. 
Hypertension 2009, 54(1):3-10. 
41. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, 
Swerdloff RS, Montori VM: Testosterone therapy in men with 
androgen deficiency syndromes: An endocrine society clinical 
practice guideline (Journal of Clinical Endocrinology and 
Metabolism (2010) 95, (2536-2559)). Journal of Clinical 
Endocrinology and Metabolism 2010, 95(8):4101. 
42. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, 
Swerdloff RS, Montori VM: Testosterone therapy in men with 
androgen deficiency syndromes: An endocrine society clinical 
practice guideline. Journal of Clinical Endocrinology and 
Metabolism 2010, 95(6):2536-2559. 
43. Jones TH: Effects of testosterone on Type 2 diabetes and 
components of the metabolic syndrome. Journal of Diabetes 2010, 
2(3):146-156. 
44. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito 
JM, Wang TJ, Knapp PE, D'Agostino RB, Sr., Bhasin S et al: 
Endogenous sex hormones and cardiovascular disease incidence 
in men. Ann Intern Med 2006, 145(3):176-184. 
45. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, 
Fagerberg B: Circulating estradiol is an independent predictor of 
progression of carotid artery intima-media thickness in middle-
aged men. J Clin Endocrinol Metab 2006, 91(11):4433-4437. 
46. Vandenplas G, De Bacquer D, Calders P, Fiers T, Kaufman JM, 
Ouwens DM, Ruige JB: Endogenous oestradiol and 
cardiovascular disease in healthy men: a systematic review and 
meta-analysis of prospective studies. Heart 2012, 98(20):1478-
1482. 
47. Abbott RD, Launer LJ, Rodriguez BL, Ross GW, Wilson PW, 
Masaki KH, Strozyk D, Curb JD, Yano K, Popper JS et al: Serum 
estradiol and risk of stroke in elderly men. Neurology 2007, 
68(8):563-568. 
48. The Coronary Drug Project. Initial findings leading to 
modifications of its research protocol. Jama 1970, 214(7):1303-
1313. 
Sex hormones and cardiovascular risk in men and women 
60 
cardiovascular complications. Asian journal of andrology 2012, 
14(2):222-225. 
38. Hakimian P, Blute M, Jr., Kashanian J, Chan S, Silver D, Shabsigh 
R: Metabolic and cardiovascular effects of androgen deprivation 
therapy. BJU international 2008, 102(11):1509-1514. 
39. Nilsson PM: The early vascular ageing (EVA) syndrome - How to 
define it? Lege Artis Medicinae 2010, 20(12):831-834. 
40. Nilsson PM, Boutouyrie P, Laurent S: Vascular aging: A tale of eva 
and ADAM in cardiovascular risk assessment and prevention. 
Hypertension 2009, 54(1):3-10. 
41. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, 
Swerdloff RS, Montori VM: Testosterone therapy in men with 
androgen deficiency syndromes: An endocrine society clinical 
practice guideline (Journal of Clinical Endocrinology and 
Metabolism (2010) 95, (2536-2559)). Journal of Clinical 
Endocrinology and Metabolism 2010, 95(8):4101. 
42. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, 
Swerdloff RS, Montori VM: Testosterone therapy in men with 
androgen deficiency syndromes: An endocrine society clinical 
practice guideline. Journal of Clinical Endocrinology and 
Metabolism 2010, 95(6):2536-2559. 
43. Jones TH: Effects of testosterone on Type 2 diabetes and 
components of the metabolic syndrome. Journal of Diabetes 2010, 
2(3):146-156. 
44. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito 
JM, Wang TJ, Knapp PE, D'Agostino RB, Sr., Bhasin S et al: 
Endogenous sex hormones and cardiovascular disease incidence 
in men. Ann Intern Med 2006, 145(3):176-184. 
45. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, 
Fagerberg B: Circulating estradiol is an independent predictor of 
progression of carotid artery intima-media thickness in middle-
aged men. J Clin Endocrinol Metab 2006, 91(11):4433-4437. 
46. Vandenplas G, De Bacquer D, Calders P, Fiers T, Kaufman JM, 
Ouwens DM, Ruige JB: Endogenous oestradiol and 
cardiovascular disease in healthy men: a systematic review and 
meta-analysis of prospective studies. Heart 2012, 98(20):1478-
1482. 
47. Abbott RD, Launer LJ, Rodriguez BL, Ross GW, Wilson PW, 
Masaki KH, Strozyk D, Curb JD, Yano K, Popper JS et al: Serum 
estradiol and risk of stroke in elderly men. Neurology 2007, 
68(8):563-568. 
48. The Coronary Drug Project. Initial findings leading to 
modifications of its research protocol. Jama 1970, 214(7):1303-
1313. 
 61 
49. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ: Increased risk of 
metabolic syndrome, diabetes mellitus, and cardiovascular 
disease in men receiving androgen deprivation therapy for 
prostate cancer. Pharmacotherapy 2008, 28(12):1511-1522. 
50. de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren 
LJ, Pols HA, de Jong FH: Associations of sex-hormone-binding 
globulin (SHBG) with non-SHBG-bound levels of testosterone 
and estradiol in independently living men. J Clin Endocrinol 
Metab 2005, 90(1):157-162. 
51. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring 
JE, Gaziano JM, Liu S: Sex hormone-binding globulin and risk of 
type 2 diabetes in women and men. N Engl J Med 2009, 
361(12):1152-1163. 
52. Lakshman KM, Bhasin S, Araujo AB: Sex hormone-binding 
globulin as an independent predictor of incident type 2 diabetes 
mellitus in men. J Gerontol A Biol Sci Med Sci 2010, 65(5):503-509. 
53. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T: 
Concentrations of sex-hormone binding globulin and 
corticosteroid binding globulin in serum in relation to 
cardiovascular risk factors and to 12-year incidence of 
cardiovascular disease and overall mortality in postmenopausal 
women. Clin Chem 1986, 32(1 Pt 1):146-152. 
54. Goodman-Gruen D, Barrett-Connor E: A prospective study of sex 
hormone-binding globulin and fatal cardiovascular disease in 
Rancho Bernardo men and women. J Clin Endocrinol Metab 1996, 
81(8):2999-3003. 
55. Laughlin GA, Goodell V, Barrett-Connor E: Extremes of 
endogenous testosterone are associated with increased risk of 
incident coronary events in older women. J Clin Endocrinol Metab 
2010, 95(2):740-747. 
56. Wild S, Pierpoint T, McKeigue P, Jacobs H: Cardiovascular disease 
in women with polycystic ovary syndrome at long-term follow-
up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 
52(5):595-600. 
57. Bernini GP, Sgro M, Moretti A, Argenio GF, Barlascini CO, 
Cristofani R, Salvetti A: Endogenous androgens and carotid 
intimal-medial thickness in women. J Clin Endocrinol Metab 1999, 
84(6):2008-2012. 
58. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, 
Szklo M: Endogenous postmenopausal hormones and carotid 
atherosclerosis: a case-control study of the atherosclerosis risk in 
communities cohort. Am J Epidemiol 2002, 155(5):437-445. 
59. Khatibi A, Agardh CD, Shakir YA, Nerbrand C, Nyberg P, Lidfeldt 
J, Samsioe G: Could androgens protect middle-aged women from 
cardiovascular events? A population-based study of Swedish 
 
61 
49. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ: Increased risk of 
metabolic syndrome, diabetes mellitus, and cardiovascular 
disease in men receiving androgen deprivation therapy for 
prostate cancer. Pharmacotherapy 2008, 28(12):1511-1522. 
50. de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren 
LJ, Pols HA, de Jong FH: Associations of sex-hormone-binding 
globulin (SHBG) with non-SHBG-bound levels of testosterone 
and estradiol in independently living men. J Clin Endocrinol 
Metab 2005, 90(1):157-162. 
51. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring 
JE, Gaziano JM, Liu S: Sex hormone-binding globulin and risk of 
type 2 diabetes in women and men. N Engl J Med 2009, 
361(12):1152-1163. 
52. Lakshman KM, Bhasin S, Araujo AB: Sex hormone-binding 
globulin as an independent predictor of incident type 2 diabetes 
mellitus in men. J Gerontol A Biol Sci Med Sci 2010, 65(5):503-509. 
53. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T: 
Concentrations of sex-hormone binding globulin and 
corticosteroid binding globulin in serum in relation to 
cardiovascular risk factors and to 12-year incidence of 
cardiovascular disease and overall mortality in postmenopausal 
women. Clin Chem 1986, 32(1 Pt 1):146-152. 
54. Goodman-Gruen D, Barrett-Connor E: A prospective study of sex 
hormone-binding globulin and fatal cardiovascular disease in 
Rancho Bernardo men and women. J Clin Endocrinol Metab 1996, 
81(8):2999-3003. 
55. Laughlin GA, Goodell V, Barrett-Connor E: Extremes of 
endogenous testosterone are associated with increased risk of 
incident coronary events in older women. J Clin Endocrinol Metab 
2010, 95(2):740-747. 
56. Wild S, Pierpoint T, McKeigue P, Jacobs H: Cardiovascular disease 
in women with polycystic ovary syndrome at long-term follow-
up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 
52(5):595-600. 
57. Bernini GP, Sgro M, Moretti A, Argenio GF, Barlascini CO, 
Cristofani R, Salvetti A: Endogenous androgens and carotid 
intimal-medial thickness in women. J Clin Endocrinol Metab 1999, 
84(6):2008-2012. 
58. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, 
Szklo M: Endogenous postmenopausal hormones and carotid 
atherosclerosis: a case-control study of the atherosclerosis risk in 
communities cohort. Am J Epidemiol 2002, 155(5):437-445. 
59. Khatibi A, Agardh CD, Shakir YA, Nerbrand C, Nyberg P, Lidfeldt 
J, Samsioe G: Could androgens protect middle-aged women from 
cardiovascular events? A population-based study of Swedish 
Sex hormones and cardiovascular risk in men and women 
62 
women: The Women's Health in the Lund Area (WHILA) Study. 
Climacteric : the journal of the International Menopause Society 
2007, 10(5):386-392. 
60. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia 
A: Role of endogenous androgens on carotid atherosclerosis in 
non-obese postmenopausal women. Nutrition, metabolism, and 
cardiovascular diseases : NMCD 2007, 17(10):705-711. 
61. Wildman RP, Colvin AB, Powell LH, Matthews KA, Everson-Rose 
SA, Hollenberg S, Johnston JM, Sutton-Tyrrell K: Associations of 
endogenous sex hormones with the vasculature in menopausal 
women: the Study of Women's Health Across the Nation 
(SWAN). Menopause 2008, 15(3):414-421. 
62. Effects of estrogen or estrogen/progestin regimens on heart 
disease risk factors in postmenopausal women. The 
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. 
The Writing Group for the PEPI Trial. Jama 1995, 273(3):199-
208. 
63. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, 
Trevisan M, Black HR, Heckbert SR, Detrano R et al: Estrogen plus 
progestin and the risk of coronary heart disease. N Engl J Med 
2003, 349(6):523-534. 
64. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg 
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson 
KC et al: Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results From the Women's 
Health Initiative randomized controlled trial. Jama 2002, 
288(3):321-333. 
65. Rastam L, Berglund G, Isacsson SO, Ryden L: The Skaraborg 
hypertension project: III. Influence on blood pressure of a 
medical care program for hypertension. Acta Med Scand 1986, 
219(3):261-269. 
66. Lindblad U, Rastam L, Ryden L, Ranstam J, Berglund G, Isacsson 
SO: Reduced stroke incidence with structured hypertension care: 
The Skaraborg Hypertension Project. J Hypertens 1990, 
8(12):1147-1153. 
67. Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, 
Rastam L: Risk factor clustering in patients with hypertension 
and non-insulin-dependent diabetes mellitus. The Skaraborg 
Hypertension Project. J Intern Med 1998, 243(3):223-232. 
68. Nyholm M, Gullberg B, Haglund B, Rastam L, Lindblad U: Higher 
education and more physical activity limit the development of 
obesity in a Swedish rural population. The Skaraborg Project. Int 
J Obes (Lond) 2008, 32(3):533-540. 
69. Rastam L, Sjonell G: A new device for measuring blood pressure 
in adults. Lancet 1991, 337(8735):249-250. 
Sex hormones and cardiovascular risk in men and women 
62 
women: The Women's Health in the Lund Area (WHILA) Study. 
Climacteric : the journal of the International Menopause Society 
2007, 10(5):386-392. 
60. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia 
A: Role of endogenous androgens on carotid atherosclerosis in 
non-obese postmenopausal women. Nutrition, metabolism, and 
cardiovascular diseases : NMCD 2007, 17(10):705-711. 
61. Wildman RP, Colvin AB, Powell LH, Matthews KA, Everson-Rose 
SA, Hollenberg S, Johnston JM, Sutton-Tyrrell K: Associations of 
endogenous sex hormones with the vasculature in menopausal 
women: the Study of Women's Health Across the Nation 
(SWAN). Menopause 2008, 15(3):414-421. 
62. Effects of estrogen or estrogen/progestin regimens on heart 
disease risk factors in postmenopausal women. The 
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. 
The Writing Group for the PEPI Trial. Jama 1995, 273(3):199-
208. 
63. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, 
Trevisan M, Black HR, Heckbert SR, Detrano R et al: Estrogen plus 
progestin and the risk of coronary heart disease. N Engl J Med 
2003, 349(6):523-534. 
64. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg 
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson 
KC et al: Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results From the Women's 
Health Initiative randomized controlled trial. Jama 2002, 
288(3):321-333. 
65. Rastam L, Berglund G, Isacsson SO, Ryden L: The Skaraborg 
hypertension project: III. Influence on blood pressure of a 
medical care program for hypertension. Acta Med Scand 1986, 
219(3):261-269. 
66. Lindblad U, Rastam L, Ryden L, Ranstam J, Berglund G, Isacsson 
SO: Reduced stroke incidence with structured hypertension care: 
The Skaraborg Hypertension Project. J Hypertens 1990, 
8(12):1147-1153. 
67. Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, 
Rastam L: Risk factor clustering in patients with hypertension 
and non-insulin-dependent diabetes mellitus. The Skaraborg 
Hypertension Project. J Intern Med 1998, 243(3):223-232. 
68. Nyholm M, Gullberg B, Haglund B, Rastam L, Lindblad U: Higher 
education and more physical activity limit the development of 
obesity in a Swedish rural population. The Skaraborg Project. Int 
J Obes (Lond) 2008, 32(3):533-540. 
69. Rastam L, Sjonell G: A new device for measuring blood pressure 
in adults. Lancet 1991, 337(8735):249-250. 
 63 
70. Obesity: preventing and managing the global epidemic. Report 
of a WHO consultation. World Health Organization technical 
report series 2000, 894:i-xii, 1-253. 
71. Opie LH: Metabolic syndrome. Circulation 2007, 115(3):e32-35. 
72. Ignell C, Berntorp K: Evaluation of the relationship between 
capillary and venous plasma glucose concentrations obtained by 
the HemoCue Glucose 201+ system during an oral glucose 
tolerance test. Scandinavian journal of clinical and laboratory 
investigation 2011, 71(8):670-675. 
73. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, 
Bown EG, Turner RC: Continuous infusion of glucose with model 
assessment: measurement of insulin resistance and beta-cell 
function in man. Diabetologia 1985, 28(7):401-411. 
74. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, 
Turner RC: Homeostasis model assessment: insulin resistance and 
beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985, 28(7):412-419. 
75. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the 
San Antonio Heart Study. Diabetes Care 1997, 20(7):1087-1092. 
76. Larsson CA, Kroll L, Bennet L, Gullberg B, Rastam L, Lindblad U: 
Leisure time and occupational physical activity in relation to 
obesity and insulin resistance: a population-based study from the 
Skaraborg Project in Sweden. Metabolism 2011. 
77. Goransson M, Hanson BS: How much can data on days with heavy 
drinking decrease the underestimation of true alcohol 
consumption? J Stud Alcohol 1994, 55(6):695-700. 
78. Idler EL, Angel RJ: Self-rated health and mortality in the 
NHANES-I Epidemiologic Follow-up Study. Am J Public Health 
1990, 80(4):446-452. 
79. 1989 guidelines for the management of mild hypertension: 
memorandum from a WHO/ISH meeting. Bull World Health 
Organ 1989, 67(5):493-498. 
80. Bennett PH: Basis of the present classification of diabetes. 
Advances in experimental medicine and biology 1985, 189:17-29. 
81. 1999 World Health Organization--International Society of 
Hypertension Guidelines for the Management of Hypertension. 
Guidelines Sub-Committee. Blood pressure Supplement 1999, 1:9-
43. 
82. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr. et al: 
The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure: the JNC 7 report. Jama 2003, 289(19):2560-2572. 
83. Alberti KGMM, Zimmet PZ: Definition, diagnosis and 
classification of diabetes mellitus and its complications. Part 1: 
 
63 
70. Obesity: preventing and managing the global epidemic. Report 
of a WHO consultation. World Health Organization technical 
report series 2000, 894:i-xii, 1-253. 
71. Opie LH: Metabolic syndrome. Circulation 2007, 115(3):e32-35. 
72. Ignell C, Berntorp K: Evaluation of the relationship between 
capillary and venous plasma glucose concentrations obtained by 
the HemoCue Glucose 201+ system during an oral glucose 
tolerance test. Scandinavian journal of clinical and laboratory 
investigation 2011, 71(8):670-675. 
73. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, 
Bown EG, Turner RC: Continuous infusion of glucose with model 
assessment: measurement of insulin resistance and beta-cell 
function in man. Diabetologia 1985, 28(7):401-411. 
74. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, 
Turner RC: Homeostasis model assessment: insulin resistance and 
beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985, 28(7):412-419. 
75. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the 
San Antonio Heart Study. Diabetes Care 1997, 20(7):1087-1092. 
76. Larsson CA, Kroll L, Bennet L, Gullberg B, Rastam L, Lindblad U: 
Leisure time and occupational physical activity in relation to 
obesity and insulin resistance: a population-based study from the 
Skaraborg Project in Sweden. Metabolism 2011. 
77. Goransson M, Hanson BS: How much can data on days with heavy 
drinking decrease the underestimation of true alcohol 
consumption? J Stud Alcohol 1994, 55(6):695-700. 
78. Idler EL, Angel RJ: Self-rated health and mortality in the 
NHANES-I Epidemiologic Follow-up Study. Am J Public Health 
1990, 80(4):446-452. 
79. 1989 guidelines for the management of mild hypertension: 
memorandum from a WHO/ISH meeting. Bull World Health 
Organ 1989, 67(5):493-498. 
80. Bennett PH: Basis of the present classification of diabetes. 
Advances in experimental medicine and biology 1985, 189:17-29. 
81. 1999 World Health Organization--International Society of 
Hypertension Guidelines for the Management of Hypertension. 
Guidelines Sub-Committee. Blood pressure Supplement 1999, 1:9-
43. 
82. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr. et al: 
The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure: the JNC 7 report. Jama 2003, 289(19):2560-2572. 
83. Alberti KGMM, Zimmet PZ: Definition, diagnosis and 
classification of diabetes mellitus and its complications. Part 1: 
Sex hormones and cardiovascular risk in men and women 
64 
Diagnosis and classification of diabetes mellitus. Provisional 
report of a WHO consultation. Diabetic Medicine 1998, 15(7):539-
553. 
84. Furuyama S, Mayes DM, Nugent CA: A radioimmunoassay for 
plasma testosterone. Steroids 1970, 16(C):415-428. 
85. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS: 
Measurement of Total Serum Testosterone in Adult Men: 
Comparison of Current Laboratory Methods Versus Liquid 
Chromatography-Tandem Mass Spectrometry. Journal of 
Clinical Endocrinology and Metabolism 2004, 89(2):534-543. 
86. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, 
Neubauer G, Klibanski A: Measurement of Free Testosterone in 
Normal Women and Women with Androgen Deficiency: 
Comparison of Methods. Journal of Clinical Endocrinology and 
Metabolism 2004, 89(2):525-533. 
87. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of 
simple methods for the estimation of free testosterone in serum. J 
Clin Endocrinol Metab 1999, 84(10):3666-3672. 
88. Morris PD, Malkin CJ, Channer KS, Jones TH: A mathematical 
comparison of techniques to predict biologically available 
testosterone in a cohort of 1072 men. Eur J Endocrinol 2004, 
151(2):241-249. 
89. Reynders M, Anckaert E, Schiettecatte J, Smitz J: Evaluation of a 
new automated electrochemiluminescent sex hormone-binding 
globulin (SHBG) immunoassay. Clinical Chemistry and 
Laboratory Medicine 2005, 43(1):86-89. 
90. Dittadi R, Fabricio ASC, Michilin S, Gion M: Evaluation of a sex 
hormone-binding globulin automated chemiluminescent assay. 
Scandinavian journal of clinical and laboratory investigation 2013, 
73(6):480-484. 
91. Task Force for the management of arterial hypertension of the 
European Society of H, Task Force for the management of arterial 
hypertension of the European Society of C: 2013 ESH/ESC 
Guidelines for the Management of Arterial Hypertension. Blood 
Press 2013, 22(4):193-278. 
92. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT et al: 
Seventh report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 2003, 42(6):1206-1252. 
93. Jones DW, Hall JE: Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure and Evidence from New Hypertension 
Trials. Hypertension 2004, 43(1):1-3. 
Sex hormones and cardiovascular risk in men and women 
64 
Diagnosis and classification of diabetes mellitus. Provisional 
report of a WHO consultation. Diabetic Medicine 1998, 15(7):539-
553. 
84. Furuyama S, Mayes DM, Nugent CA: A radioimmunoassay for 
plasma testosterone. Steroids 1970, 16(C):415-428. 
85. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS: 
Measurement of Total Serum Testosterone in Adult Men: 
Comparison of Current Laboratory Methods Versus Liquid 
Chromatography-Tandem Mass Spectrometry. Journal of 
Clinical Endocrinology and Metabolism 2004, 89(2):534-543. 
86. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, 
Neubauer G, Klibanski A: Measurement of Free Testosterone in 
Normal Women and Women with Androgen Deficiency: 
Comparison of Methods. Journal of Clinical Endocrinology and 
Metabolism 2004, 89(2):525-533. 
87. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of 
simple methods for the estimation of free testosterone in serum. J 
Clin Endocrinol Metab 1999, 84(10):3666-3672. 
88. Morris PD, Malkin CJ, Channer KS, Jones TH: A mathematical 
comparison of techniques to predict biologically available 
testosterone in a cohort of 1072 men. Eur J Endocrinol 2004, 
151(2):241-249. 
89. Reynders M, Anckaert E, Schiettecatte J, Smitz J: Evaluation of a 
new automated electrochemiluminescent sex hormone-binding 
globulin (SHBG) immunoassay. Clinical Chemistry and 
Laboratory Medicine 2005, 43(1):86-89. 
90. Dittadi R, Fabricio ASC, Michilin S, Gion M: Evaluation of a sex 
hormone-binding globulin automated chemiluminescent assay. 
Scandinavian journal of clinical and laboratory investigation 2013, 
73(6):480-484. 
91. Task Force for the management of arterial hypertension of the 
European Society of H, Task Force for the management of arterial 
hypertension of the European Society of C: 2013 ESH/ESC 
Guidelines for the Management of Arterial Hypertension. Blood 
Press 2013, 22(4):193-278. 
92. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT et al: 
Seventh report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 2003, 42(6):1206-1252. 
93. Jones DW, Hall JE: Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure and Evidence from New Hypertension 
Trials. Hypertension 2004, 43(1):1-3. 
 65 
94. Wang Y, Wang QJ: The prevalence of prehypertension and 
hypertension among US Adults According to the New Joint 
National Committee Guidelines: New challenges of the old 
problem. Arch Intern Med 2004, 164(19):2126-2134. 
95. Alpert JS, Antman E, Apple F, Armstrong PW, Bassand JP, De Luna 
AB, Beller G, Breithardt G, Chaitman BR, Clemmensen P et al: 
Myocardial infarction redefined - A consensus document of the 
Joint European Society of Cardiology/American College of 
Cardiology committee for the redefinition of myocardial 
infarction. Eur Heart J 2000, 21(18):1502-1513. 
96. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, 
Isacsson SO, Janzon L, Rastam L: Comparison of different 
procedures to identify probable cases of myocardial infarction 
and stroke in two Swedish prospective cohort studies using local 
and national routine registers. Eur J Epidemiol 2000, 16(3):235-
243. 
97. Lindblad U, Rastam L, Ranstam J, Peterson M: Validity of register 
data on acute myocardial infarction and acute stroke: the 
Skaraborg Hypertension Project. Scand J Soc Med 1993, 21(1):3-
9. 
98. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, 
Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A et 
al: Novel and conventional biomarkers for prediction of incident 
cardiovascular events in the community. Jama 2009, 302(1):49-
57. 
99. Goldstein M: Cerebrovascular disorders: A clinical and research 
classification. World Health Organization Offset Publication 1979, 
No. 43. 
100. Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund 
G, Janzon L: Geographic distribution of stroke incidence within 
an urban population: relations to socioeconomic circumstances 
and prevalence of cardiovascular risk factors. Stroke 2001, 
32(5):1098-1103. 
101. Smith JG, Platonov PG, Hedblad B, Engström G, Melander O: Atrial 
fibrillation in the Malmö diet and cancer study: A study of 
occurrence, risk factors and diagnostic validity. Eur J Epidemiol 
2010, 25(2):95-102. 
102. Ingelsson E, Arnlov J, Lind L, Sundstrom J: Metabolic syndrome 
and risk for heart failure in middle-aged men. Heart 2006, 
92(10):1409-1413. 
103. Nyholm M, Gullberg B, Haglund B, Rastam L, Lindblad U: Higher 
education and more physical activity limit the development of 
obesity in a Swedish rural population. The Skaraborg Project. Int 
J Obes (Lond) 2008, 32(3):533-540. 
 
65 
94. Wang Y, Wang QJ: The prevalence of prehypertension and 
hypertension among US Adults According to the New Joint 
National Committee Guidelines: New challenges of the old 
problem. Arch Intern Med 2004, 164(19):2126-2134. 
95. Alpert JS, Antman E, Apple F, Armstrong PW, Bassand JP, De Luna 
AB, Beller G, Breithardt G, Chaitman BR, Clemmensen P et al: 
Myocardial infarction redefined - A consensus document of the 
Joint European Society of Cardiology/American College of 
Cardiology committee for the redefinition of myocardial 
infarction. Eur Heart J 2000, 21(18):1502-1513. 
96. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, 
Isacsson SO, Janzon L, Rastam L: Comparison of different 
procedures to identify probable cases of myocardial infarction 
and stroke in two Swedish prospective cohort studies using local 
and national routine registers. Eur J Epidemiol 2000, 16(3):235-
243. 
97. Lindblad U, Rastam L, Ranstam J, Peterson M: Validity of register 
data on acute myocardial infarction and acute stroke: the 
Skaraborg Hypertension Project. Scand J Soc Med 1993, 21(1):3-
9. 
98. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, 
Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A et 
al: Novel and conventional biomarkers for prediction of incident 
cardiovascular events in the community. Jama 2009, 302(1):49-
57. 
99. Goldstein M: Cerebrovascular disorders: A clinical and research 
classification. World Health Organization Offset Publication 1979, 
No. 43. 
100. Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund 
G, Janzon L: Geographic distribution of stroke incidence within 
an urban population: relations to socioeconomic circumstances 
and prevalence of cardiovascular risk factors. Stroke 2001, 
32(5):1098-1103. 
101. Smith JG, Platonov PG, Hedblad B, Engström G, Melander O: Atrial 
fibrillation in the Malmö diet and cancer study: A study of 
occurrence, risk factors and diagnostic validity. Eur J Epidemiol 
2010, 25(2):95-102. 
102. Ingelsson E, Arnlov J, Lind L, Sundstrom J: Metabolic syndrome 
and risk for heart failure in middle-aged men. Heart 2006, 
92(10):1409-1413. 
103. Nyholm M, Gullberg B, Haglund B, Rastam L, Lindblad U: Higher 
education and more physical activity limit the development of 
obesity in a Swedish rural population. The Skaraborg Project. Int 
J Obes (Lond) 2008, 32(3):533-540. 
Sex hormones and cardiovascular risk in men and women 
66 
104. Christensen L, Hagen C, Henriksen JE, Haug E: Elevated levels of 
sex hormones and sex hormone binding globulin in male patients 
with insulin dependent diabetes mellitus. Effect of improved 
blood glucose regulation. Dan Med Bull 1997, 44(5):547-550. 
105. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, 
Flamia R, Biscotti M, Vicennati V: Insulin regulates testosterone 
and sex hormone-binding globulin concentrations in adult 
normal weight and obese men. J Clin Endocrinol Metab 1995, 
80(2):654-658. 
106. Plymate SR, Matej LA, Jones RE, Friedl KE: Inhibition of sex 
hormone-binding globulin production in the human hepatoma 
(Hep G2) cell line by insulin and prolactin. J Clin Endocrinol 
Metab 1988, 67(3):460-464. 
107. Khaw KT, Barrett-Connor E: Blood pressure and endogenous 
testosterone in men: an inverse relationship. J Hypertens 1988, 
6(4):329-332. 
108. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, 
Sundfjord J, Jorde R: Association of endogenous testosterone with 
blood pressure and left ventricular mass in men. The Tromso 
Study. Eur J Endocrinol 2004, 150(1):65-71. 
109. Wang L, Szklo M, Folsom AR, Cook NR, Gapstur SM, Ouyang P: 
Endogenous sex hormones, blood pressure change, and risk of 
hypertension in postmenopausal women: the Multi-Ethnic Study 
of Atherosclerosis. Atherosclerosis 2012, 224(1):228-234. 
110. Phillips GB, Jing TY, Laragh JH, Sealey JE: Serum sex hormone 
levels and renin-sodium profile in men with hypertension. Am J 
Hypertens 1995, 8(6):626-629. 
111. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: 
Longitudinal effects of aging on serum total and free testosterone 
levels in healthy men. Baltimore Longitudinal Study of Aging. J 
Clin Endocrinol Metab 2001, 86(2):724-731. 
112. Maggio M, Lauretani F, Basaria S, Ceda GP, Bandinelli S, Metter EJ, 
Bos AJ, Ruggiero C, Ceresini G, Paolisso G et al: Sex hormone 
binding globulin levels across the adult lifespan in women--the 
role of body mass index and fasting insulin. J Endocrinol Invest 
2008, 31(7):597-601. 
113. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, 
Mellstrom D, Ohlsson C: Low serum testosterone and estradiol 
predict mortality in elderly men. J Clin Endocrinol Metab 2009, 
94(7):2482-2488. 
114. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous 
sex hormones and the development of type 2 diabetes in older 
men and women: the Rancho Bernardo study. Diabetes Care 
2002, 25(1):55-60. 
Sex hormones and cardiovascular risk in men and women 
66 
104. Christensen L, Hagen C, Henriksen JE, Haug E: Elevated levels of 
sex hormones and sex hormone binding globulin in male patients 
with insulin dependent diabetes mellitus. Effect of improved 
blood glucose regulation. Dan Med Bull 1997, 44(5):547-550. 
105. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, 
Flamia R, Biscotti M, Vicennati V: Insulin regulates testosterone 
and sex hormone-binding globulin concentrations in adult 
normal weight and obese men. J Clin Endocrinol Metab 1995, 
80(2):654-658. 
106. Plymate SR, Matej LA, Jones RE, Friedl KE: Inhibition of sex 
hormone-binding globulin production in the human hepatoma 
(Hep G2) cell line by insulin and prolactin. J Clin Endocrinol 
Metab 1988, 67(3):460-464. 
107. Khaw KT, Barrett-Connor E: Blood pressure and endogenous 
testosterone in men: an inverse relationship. J Hypertens 1988, 
6(4):329-332. 
108. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, 
Sundfjord J, Jorde R: Association of endogenous testosterone with 
blood pressure and left ventricular mass in men. The Tromso 
Study. Eur J Endocrinol 2004, 150(1):65-71. 
109. Wang L, Szklo M, Folsom AR, Cook NR, Gapstur SM, Ouyang P: 
Endogenous sex hormones, blood pressure change, and risk of 
hypertension in postmenopausal women: the Multi-Ethnic Study 
of Atherosclerosis. Atherosclerosis 2012, 224(1):228-234. 
110. Phillips GB, Jing TY, Laragh JH, Sealey JE: Serum sex hormone 
levels and renin-sodium profile in men with hypertension. Am J 
Hypertens 1995, 8(6):626-629. 
111. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: 
Longitudinal effects of aging on serum total and free testosterone 
levels in healthy men. Baltimore Longitudinal Study of Aging. J 
Clin Endocrinol Metab 2001, 86(2):724-731. 
112. Maggio M, Lauretani F, Basaria S, Ceda GP, Bandinelli S, Metter EJ, 
Bos AJ, Ruggiero C, Ceresini G, Paolisso G et al: Sex hormone 
binding globulin levels across the adult lifespan in women--the 
role of body mass index and fasting insulin. J Endocrinol Invest 
2008, 31(7):597-601. 
113. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, 
Mellstrom D, Ohlsson C: Low serum testosterone and estradiol 
predict mortality in elderly men. J Clin Endocrinol Metab 2009, 
94(7):2482-2488. 
114. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous 
sex hormones and the development of type 2 diabetes in older 
men and women: the Rancho Bernardo study. Diabetes Care 
2002, 25(1):55-60. 
 67 
115. Fukui M, Ose H, Kitagawa Y, Yamazaki M, Hasegawa G, 
Yoshikawa T, Nakamura N: Relationship between low serum 
endogenous androgen concentrations and arterial stiffness in 
men with type 2 diabetes mellitus. Metabolism 2007, 56(9):1167-
1173. 
116. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction 
of clinical cardiovascular events with carotid intima-media 
thickness: a systematic review and meta-analysis. Circulation 
2007, 115(4):459-467. 
117. Kardia SR, Chu J, Sowers MR: Characterizing Variation in Sex 
Steroid Hormone Pathway Genes in Women of 4 
Races/Ethnicities: The Study of Women's Health Across the 
Nation (SWAN). American Journal of Medicine 2006, 119(9 
SUPPL. 1):S3-S15. 
118. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia SR: Sex 
Steroid Hormone Pathway Genes and Health-Related Measures 
in Women of 4 Races/Ethnicities: The Study of Women's Health 
Across the Nation (SWAN). American Journal of Medicine 2006, 
119(9 SUPPL. 1):S103-S110. 
119. Daka B, Rosen T, Jansson PA, Larsson CA, Rastam L, Lindblad U: 
Low sex hormone-binding globulin is associated with 
hypertension: a cross-sectional study in a Swedish population. 
BMC Cardiovasc Disord 2013, 13(1):30. 
120. Ostgren CJ, Merlo J, Rastam L, Lindblad U: Atrial fibrillation and 
its association with type 2 diabetes and hypertension in a Swedish 
community. Diabetes Obes Metab 2004, 6(5):367-374. 
121. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA: Sex 
hormone-binding globulin: anatomy and physiology of a new 
regulatory system. J Steroid Biochem Mol Biol 1991, 40(4-6):813-
820. 
122. Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz 
H, Metzger J, Schweigert FJ, Luppa PB, Nykjaer A et al: Role of 
endocytosis in cellular uptake of sex steroids. Cell 2005, 
122(5):751-762. 
123. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata 
C, Ichio N, Wada K, Hasegawa G, Yoshikawa T: Association 
between serum testosterone concentration and carotid 
atherosclerosis in men with type 2 diabetes. Diabetes Care 2003, 
26(6):1869-1873. 
124. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, 
Morales AM, Volterrani M, Yellowlees A, Howell JD et al: 
Testosterone replacement in hypogonadal men with Type 2 
diabetes and/or metabolic syndrome (the TIMES2 study). 
Diabetes Care 2011, 34(4):828-837. 
 
67 
115. Fukui M, Ose H, Kitagawa Y, Yamazaki M, Hasegawa G, 
Yoshikawa T, Nakamura N: Relationship between low serum 
endogenous androgen concentrations and arterial stiffness in 
men with type 2 diabetes mellitus. Metabolism 2007, 56(9):1167-
1173. 
116. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction 
of clinical cardiovascular events with carotid intima-media 
thickness: a systematic review and meta-analysis. Circulation 
2007, 115(4):459-467. 
117. Kardia SR, Chu J, Sowers MR: Characterizing Variation in Sex 
Steroid Hormone Pathway Genes in Women of 4 
Races/Ethnicities: The Study of Women's Health Across the 
Nation (SWAN). American Journal of Medicine 2006, 119(9 
SUPPL. 1):S3-S15. 
118. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia SR: Sex 
Steroid Hormone Pathway Genes and Health-Related Measures 
in Women of 4 Races/Ethnicities: The Study of Women's Health 
Across the Nation (SWAN). American Journal of Medicine 2006, 
119(9 SUPPL. 1):S103-S110. 
119. Daka B, Rosen T, Jansson PA, Larsson CA, Rastam L, Lindblad U: 
Low sex hormone-binding globulin is associated with 
hypertension: a cross-sectional study in a Swedish population. 
BMC Cardiovasc Disord 2013, 13(1):30. 
120. Ostgren CJ, Merlo J, Rastam L, Lindblad U: Atrial fibrillation and 
its association with type 2 diabetes and hypertension in a Swedish 
community. Diabetes Obes Metab 2004, 6(5):367-374. 
121. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA: Sex 
hormone-binding globulin: anatomy and physiology of a new 
regulatory system. J Steroid Biochem Mol Biol 1991, 40(4-6):813-
820. 
122. Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz 
H, Metzger J, Schweigert FJ, Luppa PB, Nykjaer A et al: Role of 
endocytosis in cellular uptake of sex steroids. Cell 2005, 
122(5):751-762. 
123. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata 
C, Ichio N, Wada K, Hasegawa G, Yoshikawa T: Association 
between serum testosterone concentration and carotid 
atherosclerosis in men with type 2 diabetes. Diabetes Care 2003, 
26(6):1869-1873. 
124. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, 
Morales AM, Volterrani M, Yellowlees A, Howell JD et al: 
Testosterone replacement in hypogonadal men with Type 2 
diabetes and/or metabolic syndrome (the TIMES2 study). 
Diabetes Care 2011, 34(4):828-837. 
Sex hormones and cardiovascular risk in men and women 
68 
125. Sonmez A, Haymana C, Bolu E, Aydogdu A, Tapan S, Serdar M, 
Altun B, Barcin C, Taslipinar A, Meric C et al: Metabolic syndrome 
and the effect of testosterone treatment in young men with 
congenital hypogonadotropic hypogonadism. European Journal of 
Endocrinology 2011, 164(5):759-764. 
126. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, 
Straub RH: Sex hormones influence on the immune system: Basic 
and clinical aspects in autoimmunity. Lupus 2004, 13(9):635-638. 
127. Monroe AK, Dobs AS: The effect of androgens on lipids. Current 
Opinion in Endocrinology, Diabetes and Obesity 2013, 20(2):132-
139. 
128. Høst C, Gormsen LC, Christensen B, Jessen N, Hougaard DM, 
Christiansen JS, Pedersen SB, Jensen MD, Nielsen S, Gravholt CH: 
Independent effects of testosterone on lipid oxidation and VLDL-
TG production: A randomized, double-blind, placebo-controlled, 
crossover study. Diabetes 2013, 62(5):1409-1416. 
129. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, 
Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME 
et al: Association of testosterone therapy with mortality, 
myocardial infarction, and stroke in men with low testosterone 
levels. Jama 2013, 310(17):1829-1836. 
130. Larsson CA, Gullberg B, Merlo J, Rastam L, Lindblad U: Female 
advantage in AMI mortality is reversed in patients with type 2 
diabetes in the Skaraborg Project. Diabetes Care 2005, 
28(9):2246-2248. 
131. Ring HZ, Lessov CN, Reed T, Marcus R, Holloway L, Swan GE, 
Carmelli D: Heritability of plasma sex hormones and hormone 
binding globulin in adult male twins. Journal of Clinical 
Endocrinology and Metabolism 2005, 90(6):3653-3658. 
132. Jaquish CE, Blangero J, Haffner SM, Stern MP, MacCluer JW: 
Quantitative genetics of serum sex hormone-binding globulin 
levels in participants in the San Antonio Family Heart Study. 
Metabolism 1997, 46(9):988-991. 
133. Groves RM: Nonresponse rates and nonresponse bias in 
household surveys. Public Opinion Quarterly 2006, 70(5):646-675. 
134. Caspi O: The JNC 7 hypertension guidelines. Jama 2003, 
290(10):1313; author reply 1314-1315. 
135. Lindblad U, Rastam L, Ranstam J, Peterson M: Validity of register 
data on acute myocardial infarction and acute stroke: the 
Skaraborg Hypertension Project. Scand J Soc Med 1993, 21(1):3-
9. 
136. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, 
Isacsson SO, Janzon L, Råstam L: Comparison of different 
procedures to identify probable cases of myocardial infarction 
and stroke in two Swedish prospective cohort studies using local 
Sex hormones and cardiovascular risk in men and women 
68 
125. Sonmez A, Haymana C, Bolu E, Aydogdu A, Tapan S, Serdar M, 
Altun B, Barcin C, Taslipinar A, Meric C et al: Metabolic syndrome 
and the effect of testosterone treatment in young men with 
congenital hypogonadotropic hypogonadism. European Journal of 
Endocrinology 2011, 164(5):759-764. 
126. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, 
Straub RH: Sex hormones influence on the immune system: Basic 
and clinical aspects in autoimmunity. Lupus 2004, 13(9):635-638. 
127. Monroe AK, Dobs AS: The effect of androgens on lipids. Current 
Opinion in Endocrinology, Diabetes and Obesity 2013, 20(2):132-
139. 
128. Høst C, Gormsen LC, Christensen B, Jessen N, Hougaard DM, 
Christiansen JS, Pedersen SB, Jensen MD, Nielsen S, Gravholt CH: 
Independent effects of testosterone on lipid oxidation and VLDL-
TG production: A randomized, double-blind, placebo-controlled, 
crossover study. Diabetes 2013, 62(5):1409-1416. 
129. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, 
Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME 
et al: Association of testosterone therapy with mortality, 
myocardial infarction, and stroke in men with low testosterone 
levels. Jama 2013, 310(17):1829-1836. 
130. Larsson CA, Gullberg B, Merlo J, Rastam L, Lindblad U: Female 
advantage in AMI mortality is reversed in patients with type 2 
diabetes in the Skaraborg Project. Diabetes Care 2005, 
28(9):2246-2248. 
131. Ring HZ, Lessov CN, Reed T, Marcus R, Holloway L, Swan GE, 
Carmelli D: Heritability of plasma sex hormones and hormone 
binding globulin in adult male twins. Journal of Clinical 
Endocrinology and Metabolism 2005, 90(6):3653-3658. 
132. Jaquish CE, Blangero J, Haffner SM, Stern MP, MacCluer JW: 
Quantitative genetics of serum sex hormone-binding globulin 
levels in participants in the San Antonio Family Heart Study. 
Metabolism 1997, 46(9):988-991. 
133. Groves RM: Nonresponse rates and nonresponse bias in 
household surveys. Public Opinion Quarterly 2006, 70(5):646-675. 
134. Caspi O: The JNC 7 hypertension guidelines. Jama 2003, 
290(10):1313; author reply 1314-1315. 
135. Lindblad U, Rastam L, Ranstam J, Peterson M: Validity of register 
data on acute myocardial infarction and acute stroke: the 
Skaraborg Hypertension Project. Scand J Soc Med 1993, 21(1):3-
9. 
136. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, 
Isacsson SO, Janzon L, Råstam L: Comparison of different 
procedures to identify probable cases of myocardial infarction 
and stroke in two Swedish prospective cohort studies using local 
 69 
and national routine registers. Eur J Epidemiol 2000, 16(3):235-
243. 
137. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, 
Rosengren A, Andersson OK: Diabetes in treated hypertension is 
common and carries a high cardiovascular risk: Results from a 
28-year follow-up. J Hypertens 2007, 25(6):1311-1317. 
138. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, 
Gudbjörnsdottir S: Risk prediction of cardiovascular disease in 
type 2 diabetes. Diabetes Care 2008, 31(10):2038-2043. 
139. Saleh N, Petursson P, Lagerqvist B, Skúladóttir H, Svensson A, 
Eliasson B, Gudbjörnsdottir S, Eeg-Olofsson K, Norhammar A: 
Long-term mortality in patients with type 2 diabetes undergoing 
coronary angiography: The impact of glucose-lowering 
treatment. Diabetologia 2012, 55(8):2109-2117. 
140. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, 
Gudbjörnsdottir S, Cederholm J: A new model for 5-year risk of 
cardiovascular disease in type 2 diabetes, from the Swedish 
National Diabetes Register (NDR). Diabetes Res Clin Pract 2011, 
93(2):276-284. 
141. Wang H, Steffen LM, Jacobs DR, Zhou X, Blackburn H, Berger AK, 
Filion KB, Luepker RV: Trends in cardiovascular risk factor 
levels in the Minnesota Heart Survey (1980-2002) as compared 
with the National Health and Nutrition Examination Survey 
(1976-2002): A partial explanation for Minnesota's low 
cardiovascular disease mortality? Am J Epidemiol 2011, 
173(5):526-538. 
142. Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, 
Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J: 
Challenges of subgroup analyses in multinational clinical trials: 
experiences from the MERIT-HF trial. American heart journal 
2001, 142(3):502-511. 
143. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose 
tolerance and impaired fasting glycaemia: the current status on 
definition and intervention. Diabet Med 2002, 19(9):708-723. 
144. Jansen SC, Temme EH, Schouten EG: Lifetime estrogen exposure 
versus age at menopause as mortality predictor. Maturitas 2002, 
43(2):105-112. 
145. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga 
JD, van der Graaf Y: Endogenous estrogen exposure and 
cardiovascular mortality risk in postmenopausal women. Am J 
Epidemiol 2002, 155(4):339-345. 
146. Rosner W, Vesper H: Toward excellence in testosterone testing: a 
consensus statement. J Clin Endocrinol Metab 2010, 95(10):4542-
4548. 
 
69 
and national routine registers. Eur J Epidemiol 2000, 16(3):235-
243. 
137. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, 
Rosengren A, Andersson OK: Diabetes in treated hypertension is 
common and carries a high cardiovascular risk: Results from a 
28-year follow-up. J Hypertens 2007, 25(6):1311-1317. 
138. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, 
Gudbjörnsdottir S: Risk prediction of cardiovascular disease in 
type 2 diabetes. Diabetes Care 2008, 31(10):2038-2043. 
139. Saleh N, Petursson P, Lagerqvist B, Skúladóttir H, Svensson A, 
Eliasson B, Gudbjörnsdottir S, Eeg-Olofsson K, Norhammar A: 
Long-term mortality in patients with type 2 diabetes undergoing 
coronary angiography: The impact of glucose-lowering 
treatment. Diabetologia 2012, 55(8):2109-2117. 
140. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, 
Gudbjörnsdottir S, Cederholm J: A new model for 5-year risk of 
cardiovascular disease in type 2 diabetes, from the Swedish 
National Diabetes Register (NDR). Diabetes Res Clin Pract 2011, 
93(2):276-284. 
141. Wang H, Steffen LM, Jacobs DR, Zhou X, Blackburn H, Berger AK, 
Filion KB, Luepker RV: Trends in cardiovascular risk factor 
levels in the Minnesota Heart Survey (1980-2002) as compared 
with the National Health and Nutrition Examination Survey 
(1976-2002): A partial explanation for Minnesota's low 
cardiovascular disease mortality? Am J Epidemiol 2011, 
173(5):526-538. 
142. Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, 
Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J: 
Challenges of subgroup analyses in multinational clinical trials: 
experiences from the MERIT-HF trial. American heart journal 
2001, 142(3):502-511. 
143. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose 
tolerance and impaired fasting glycaemia: the current status on 
definition and intervention. Diabet Med 2002, 19(9):708-723. 
144. Jansen SC, Temme EH, Schouten EG: Lifetime estrogen exposure 
versus age at menopause as mortality predictor. Maturitas 2002, 
43(2):105-112. 
145. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga 
JD, van der Graaf Y: Endogenous estrogen exposure and 
cardiovascular mortality risk in postmenopausal women. Am J 
Epidemiol 2002, 155(4):339-345. 
146. Rosner W, Vesper H: Toward excellence in testosterone testing: a 
consensus statement. J Clin Endocrinol Metab 2010, 95(10):4542-
4548. 
Sex hormones and cardiovascular risk in men and women 
70 
147. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H: Position 
statement: Utility, limitations, and pitfalls in measuring 
testosterone: an Endocrine Society position statement. J Clin 
Endocrinol Metab 2007, 92(2):405-413. 
148. Plymate SR, Tenover JS, Bremner WJ: Circadian variation in 
testosterone, sex hormone-binding globulin, and calculated non-
sex hormone-binding globulin bound testosterone in healthy 
young and elderly men. J Androl 1989, 10(5):366-371. 
 
 
Sex hormones and cardiovascular risk in men and women 
70 
147. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H: Position 
statement: Utility, limitations, and pitfalls in measuring 
testosterone: an Endocrine Society position statement. J Clin 
Endocrinol Metab 2007, 92(2):405-413. 
148. Plymate SR, Tenover JS, Bremner WJ: Circadian variation in 
testosterone, sex hormone-binding globulin, and calculated non-
sex hormone-binding globulin bound testosterone in healthy 
young and elderly men. J Androl 1989, 10(5):366-371. 
 
 
